<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-178" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Selecting a Treatment Modality in Acute Coronary Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Petrovic</surname>
            <given-names>Luka</given-names>
          </name>
          <aff>Rutgers NJMS, Newark</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chhabra</surname>
            <given-names>Lovely</given-names>
          </name>
          <aff>New York Medical College</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Luka Petrovic declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Lovely Chhabra declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-178.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Acute coronary syndrome (ACS) is a commonly encountered diagnosis and a common reason for inpatient admission. Timely identification of this condition, appropriate choice of treatment, and adequate administration of medication impacts morbidity and mortality tremendously. This activity will review the modalities used to treat patients with ACS, with particular focus on the appropriate selection of agents and interventions based on clinical characteristics of patients and the most current available evidence. The role of the interprofessional team in improving outcomes will be reviewed.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Outline the general components of the treatment of patients with acute coronary syndrome (ACS).</p></list-item><list-item><p>Summarize the findings from the most recent clinic trials regarding antiplatelet therapy in patients with atrial fibrillation undergoing primary percutaneous coronary intervention.</p></list-item><list-item><p>Identify patients at the highest risk of mortality from acute coronary syndrome.</p></list-item><list-item><p>Describe the importance of interprofessional teamwork in the effective care of patients with acute coronary syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=178&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=178">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-178.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Acute coronary syndrome (ACS) is one of the manifestations of ischemic heart disease.<xref ref-type="bibr" rid="article-178.r1">[1]</xref><xref ref-type="bibr" rid="article-178.r2">[2]</xref> The term is used to describe any constellation of symptoms that suggests that acute myocardial ischemia is occurring.<xref ref-type="bibr" rid="article-178.r1">[1]</xref> ACS encompasses the following clinical entities: unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). The most common mechanism for acute myocardial ischemia represents coronary artery plaque rupture that results in thrombosis and leads to either partial or complete occlusion of the coronary artery.<xref ref-type="bibr" rid="article-178.r3">[3]</xref> Other mechanisms of acute myocardial ischemia requiring acknowledgment in the current era where effective medical therapy significantly decreased the risk of plaque rupture are plaque erosion, microvascular disease, vasospasm, and restenosis after stenting.<xref ref-type="bibr" rid="article-178.r4">[4]</xref> The basis for UA and NSTEMI differentiation is the presence of biomarkers of myocardial damage (cardiac-specific troponins) in the blood sample of patients with NSTEMI and the lack of those in patients with UA. STEMI refers to acute coronary syndrome accompanied with ST elevations in the electrocardiogram (ECG) with concomitant or subsequent appearance of biomarkers of myocardial injury.<xref ref-type="bibr" rid="article-178.r5">[5]</xref> The estimated prevalence of coronary artery disease in the United States of America (USA), including myocardial infarction (MI), is around 6% of the population.<xref ref-type="bibr" rid="article-178.r6">[6]</xref> In 2008, a report stated the incidence rate of STEMI in the USA was about 50 per 100000 and showing a decreasing trend when compared to earlier years.<xref ref-type="bibr" rid="article-178.r7">[7]</xref>&#x000a0;The national registry of MI reported 2.5 million cases of MI between 1990 and 2006 and additionally demonstrated an increase in the proportion of the cases caused by NSTEMI from 14.2% to 59.1% during the registry timeframe.<xref ref-type="bibr" rid="article-178.r8">[8]</xref> Numerous factors influence the mortality of patients with STEMI,&#x000a0;but the details of these epidemiologic characteristics are beyond the scope of this document. Certain angiography registries report 1-year mortality in STEMI patients to be generally around 10%.<xref ref-type="bibr" rid="article-178.r9">[9]</xref><xref ref-type="bibr" rid="article-178.r10">[10]</xref> Some studies demonstrate that short-term mortality in patients with NSTEMI is lower than patients with STEMI, but as the follow-up extends to 2 years, mortality rates become comparable.<xref ref-type="bibr" rid="article-178.r11">[11]</xref></p>
      </sec>
      <sec id="article-178.s3" sec-type="Function">
        <title>Function</title>
        <p>The pharmacologic treatment of ACS can be broken down into several groups of medications that improve survival, decrease recurrent ischemic events, and provide symptomatic relief. Choosing an adequate treatment modality in ACS involves several critical decisions.&#x000a0;It is essential to distinguish&#x000a0;STEMI patients from those who are experiencing NSTEMI or UA. This distinction further impacts the priorities, timing, and selection of&#x000a0;pharmacotherapy used in different patients with&#x000a0;ACS.</p>
        <p>First is a review of the choice of treatment modalities in patients with STEMI. In this group of patients, the most important objective is to provide timely reperfusion modality with the goal of ischemic time being less than 120 minutes. Ischemic time refers to the time from onset of symptoms to the administration of reperfusion therapy. Reperfusion therapy can be a fibrinolytic agent or a form of percutaneous coronary intervention (PCI). The choice of the reperfusion strategy will depend on the estimation of the time that will be necessary for the administration of reperfusion therapy. In the case of fibrinolysis, that time is referred to as door-to-needle, while in the case of PCI, it is door-to-balloon time. PCI is the preferred reperfusion strategy in all patients with STEMI presenting within 12 hours of symptom onset with the condition that it must be done 120 minutes from STEMI diagnosis.<xref ref-type="bibr" rid="article-178.r7">[7]</xref> Apart from promptly restoring the coronary flow by reopening the culprit artery, it also provides definitive diagnostic modality for a comprehensive assessment of coronary anatomy, hemodynamic data, determines the need for coronary artery bypass surgery (CABG), and provides prognostic data related to short-term and long-term mortality by calculating the thrombolysis in myocardial infarction (TIMI) flow grade or TIMI frame count.<xref ref-type="bibr" rid="article-178.r12">[12]</xref> PCI should also be considered in patients presenting with symptoms that last more than 12 hours, which also have clinical evidence of ongoing ischemia, hemodynamic instability, malignant arrhythmias, or heart failure. The detailed discussion about the choice of vascular access, revascularization technique, and the optimal type of stent, along with the approach to non-culprit lesions, is out of the scope of this review. Briefly, European guidelines from 2017 indicate that the stent deployment should be into the culprit artery, and a drug-eluting stent (DES) is preferable to a bare-metal stent (BMS) for primary PCI. Also, radial access may be preferred over femoral access when performed by an experienced operator.<xref ref-type="bibr" rid="article-178.r7">[7]</xref></p>
        <p>Fibrinolysis should be a consideration if the patient first presents to a non-PCI capable facility and the anticipated time from first medical contact to the performance of primary PCI exceeds 120 minutes (this 120-minute duration usually accounts for a 30-minute door in-door out time (DIDO) time goal at the non-PCI capable facility). Upon deciding about whether or not to use fibrinolysis, it should preferably occur within the first 30 minutes of the first medical contact. This strategy can be achieved either as prehospital fibrinolysis by the emergency medical service (EMS) provider or within 30 minutes of arriving at a non-PCI capable facility (door to needle time). Contraindications to fibrinolysis require prompt review if this strategy is an option. Absolute contraindications are any previous intracranial hemorrhage, ischemic stroke in the past 3 months, central nervous system neoplasm or arteriovenous malformation, major head trauma or surgery within the past month, known active bleeding or bleeding diathesis (with the exception of menses), suspected aortic dissection, severe uncontrolled hypertension unresponsive to emergent medical therapy and use of streptokinase in the last 6 months.<xref ref-type="bibr" rid="article-178.r7">[7]</xref> Some relative contraindications include a history of chronic poorly controlled hypertension, surgery in the last 3 months, ischemic stroke more than 3 months ago, traumatic or prolonged cardiopulmonary resuscitation (CPR), and any other unspecified intracranial pathology. Some factors merit consideration when considering fibrinolysis based on the available evidence from the recent clinical studies. Mortality reduction in patients with STEMI who are undergoing fibrinolysis is the highest within the first 4 hours, being around 80% after 2 hours and less than 20% after 4 hours of symptom onset.<xref ref-type="bibr" rid="article-178.r13">[13]</xref> Patients with developed collateral circulation may have more significant benefits beyond the 2-hour timeframe when compared to patients without collateral circulation. The CAPTIM trial compared prehospital fibrinolysis with PCI in patients with STEMI and found that patients who received treatment with pre-hospital fibrinolysis within 2 hours of symptoms onset had better survival when compared to PCI strategy.<xref ref-type="bibr" rid="article-178.r14">[14]</xref> Based on the STREAM trial, prehospital fibrinolysis provides similar efficacy when compared to PCI in patients with STEMI who presented within 3 hours and were unable to get PCI within 1 hour but with a higher rate of intracranial bleeding.<xref ref-type="bibr" rid="article-178.r15">[15]</xref><xref ref-type="bibr" rid="article-178.r16">[16]</xref> An overview of nine randomized trials published by the Fibrinolytic Therapy Trialist collaborative group suggests that characteristics of patients who derive the least benefit from fibrinolysis are those with a delayed presentation (over 13 to 24 hours of symptom onset), elderly (age greater than 75 years), inferior ST elevations, and uncontrolled hypertension (systolic blood pressure (BP) more than 175 mmHg).<xref ref-type="bibr" rid="article-178.r17">[17]</xref> Thus, as a general framework, it seems that patients who present with early onset of symptoms but with a significant anticipated delay in transportation to a PCI-capable facility should get fibrinolytic treatment in the absence of absolute contraindications. While on the other hand, patients who present with onset of symptoms longer than 12 hours and absence of hemodynamic instability and evidence of ongoing ischemia of a large amount of myocardium should not receive fibrinolysis due to a likely lack of significant benefit. Other cases require evaluation on a case-by-case basis with careful consideration of risks and benefits. Upon deciding for a fibrinolytic strategy, agents that are fibrin-specific and given as a bolus (such as tenecteplase and reteplase) are preferred to other agents due to demonstrated lower risk of intracerebral bleeding and are more convenient to use.<xref ref-type="bibr" rid="article-178.r18">[18]</xref><xref ref-type="bibr" rid="article-178.r19">[19]</xref></p>
        <p>Concomitantly with the decision of reperfusion strategy, it is of paramount importance to institute appropriate antiplatelet and anticoagulation treatment in patients with STEMI. Differences in approach exist depending on the selected reperfusion strategy. In all patients, regardless if they are undergoing PCI or fibrinolysis, aspirin should be administered as early as possible.<xref ref-type="bibr" rid="article-178.r20">[20]</xref><xref ref-type="bibr" rid="article-178.r21">[21]</xref><xref ref-type="bibr" rid="article-178.r22">[22]</xref> The aspirin loading dose should be oral 162 to 325 mg. The already chosen reperfusion strategy influences the choice of the second antiplatelet agent. In patients undergoing primary PCI, current evidence supports the use of oral ticagrelor with a loading dose of 180mg and maintenance dose of 90 mg twice daily or oral prasugrel with a loading dose of 60 mg and maintenance dose of 10 mg daily or clopidogrel with a 600 mg loading dose with subsequent dosing of 75 mg daily.<xref ref-type="bibr" rid="article-178.r22">[22]</xref><xref ref-type="bibr" rid="article-178.r23">[23]</xref><xref ref-type="bibr" rid="article-178.r24">[24]</xref><xref ref-type="bibr" rid="article-178.r25">[25]</xref> Contraindications to prasugrel include a history of ischemic stroke and/or transient ischemic attack.<xref ref-type="bibr" rid="article-178.r25">[25]</xref><xref ref-type="bibr" rid="article-178.r26">[26]</xref>&#x000a0;The intravenous formulation of P2Y12 cangrelor could be an option in situations where quick on and off action of platelet inhibition is required and especially in patients who have not been pretreated with oral adenosine-diphosphate (ADP) antagonists,<xref ref-type="bibr" rid="article-178.r27">[27]</xref><xref ref-type="bibr" rid="article-178.r28">[28]</xref> or in situations where patients cannot absorb orally. In regards to the timing of the initial dose of P2Y12 in patients with STEMI undergoing PCI, current guidelines support a loading dose with the diagnosis of STEMI, although there exists a substantial variation in practice. Namely, giving the initial loading dose during PCI, after delineation of the coronary anatomy. Finally, GpIIb/IIIa inhibitors are useful in certain patients. Evidence to support the use of intravenous GP IIb/IIIa receptor antagonists in STEMI was largely established before the use of oral dual antiplatelet therapy. Although prior several studies have failed to show a significant benefit of &#x0201c;upstream&#x0201d; GP IIb/IIIa receptor antagonists use before primary PCI in the setting of dual antiplatelet therapy with either intravenous heparin or bivalirudin, its role is restricted to the use of abciximab based on a meta-analysis which suggested that adjunctive abciximab may be useful in this setting. The adjunctive use of GP IIb/IIIa agents at the time of PCI can be considered in selective situations and on a case-to-case basis, especially for patients with a large thrombus burden or inadequate P2Y12 antagonist loading. In those receiving bivalirudin, the routine adjunctive use of GP IIb/IIIa inhibitors is not recommended, except for &#x0201c;bail-out&#x0201d; therapy in selected cases.<xref ref-type="bibr" rid="article-178.r29">[29]</xref><xref ref-type="bibr" rid="article-178.r30">[30]</xref><xref ref-type="bibr" rid="article-178.r31">[31]</xref></p>
        <p>In patients with STEMI who are undergoing fibrinolysis, clopidogrel is the recommended P2Y12 inhibitor.<xref ref-type="bibr" rid="article-178.r32">[32]</xref><xref ref-type="bibr" rid="article-178.r33">[33]</xref> Based on trials that evaluated the use of clopidogrel in this clinical setting, the loading dose in this scenario is 300 mg, administered as soon as possible, followed by maintenance of 75 mg daily. In patients who are older than 75 years, only 75 mg of clopidogrel is the recommended loading dose. Ticagrelor and prasugrel have not been sufficiently investigated in these patients and are not recommended as adjunctive loading therapy, as there might be an increased bleeding risk given the higher potency of these agents. TREAT trial suggests that ticagrelor may be potentially safe in patients with ACS pretreated with clopidogrel who underwent fibrinolytic therapy when administered around 12 hours after the clopidogrel dose.<xref ref-type="bibr" rid="article-178.r34">[34]</xref> The use of GpIIb/IIIa inhibitors in patients with STEMI who are undergoing fibrinolysis is not recommended.<xref ref-type="bibr" rid="article-178.r7">[7]</xref></p>
        <p>Anticoagulant agents for consideration in patients with STEMI undergoing primary PCI are unfractionated heparin (UFH), low molecular weight heparin (LMWH), and bivalirudin.<xref ref-type="bibr" rid="article-178.r7">[7]</xref> Early evidence for the efficacy of UFH in patients with STEMI comes from the pre-fibrinolytic era. With the introduction of fibrinolysis, the publication of ISIS-2, and subsequent introduction of aspirin, the risk and benefit from the addition of UFH to fibrinolytic agents changed, but most of the evidence points out to small, but the significant net benefit of UFH when combined with aspirin versus aspirin alone in patients treated with fibrinolysis.<xref ref-type="bibr" rid="article-178.r12">[12]</xref> The well-known, small, randomized trial that compared UFH to enoxaparin was the ATOLL trial.<xref ref-type="bibr" rid="article-178.r35">[35]</xref> Around 900 STEMI patients, who received therapy with aspirin, clopidogrel, and Gp IIb/IIIAa inhibitors (in about 80% of patients) were randomized to UFH versus enoxaparin before primary PCI, and the primary outcome of death, MI complications, procedure failure, or major bleeding showed a non-significant reduction in the enoxaparin group. Data from this trial cannot be extrapolated to patients not treated with GpIIb/IIIa inhibitors and patients treated with ticagrelor or prasugrel. A meta-analysis that took place in 2012, including a large number of trials, demonstrated that enoxaparin was superior to UFH, although the study had limitations due to the inclusion of data from non-randomized trials too. A meta-analysis by Hai-Long et al. in 2018<xref ref-type="bibr" rid="article-178.r36">[36]</xref><xref ref-type="bibr" rid="article-178.r37">[37]</xref>&#x000a0;demonstrated a reduced incidence of MI and death in patients with STEMI treated with enoxaparin compared to UFH, without a difference in major bleeding. At present, the latest European Society guidelines for STEMI recommend UFH as the preferred agent, but enoxaparin remains a reasonably safe and alternate consideration. The studies which evaluated bivalirudin use in patients with STEMI undergoing PCI demonstrated a higher incidence of stent thrombosis.<xref ref-type="bibr" rid="article-178.r38">[38]</xref> A subgroup of large observational SWEDEHEART study included STEMI patients treated with UFH compared to bivalirudin and demonstrated similar rates of early stent thrombosis, while patients treated with UFH had increased mortality.<xref ref-type="bibr" rid="article-178.r39">[39]</xref> Due to limited evidence for routine use of bivalirudin, currently, it remains a safe option to use bivalirudin in patients with heparin-induced thrombocytopenia.</p>
        <p>For patients with STEMI who are undergoing fibrinolysis, an anticoagulant is necessary until revascularization occurs. If there is no planned revascularization, it should be administered at least 48 hours, up to 8 days.<xref ref-type="bibr" rid="article-178.r12">[12]</xref><xref ref-type="bibr" rid="article-178.r7">[7]</xref> Trials such as ASSENT 3 and ExTRACT-TIMI 25 demonstrated the benefit of enoxaparin when compared to UFH, although the latter study showed increased non-cerebral bleeding complications in patients treated with enoxaparin. The study also included patients with creatinine clearance less than 30 mL/min and patients older than 75 with appropriate dose adjustment.<xref ref-type="bibr" rid="article-178.r40">[40]</xref><xref ref-type="bibr" rid="article-178.r41">[41]</xref>&#x000a0;It seems reasonable to prefer enoxaparin over UFH in patients with STEMI undergoing fibrinolysis, although guidelines suggest class I recommendation for both agents.<xref ref-type="bibr" rid="article-178.r12">[12]</xref><xref ref-type="bibr" rid="article-178.r7">[7]</xref></p>
        <p>Other general pharmacologic therapy that needs to be chosen and considered in all patients with STEMI includes beta-blockers, nitrates, analgesics, and inhibitors of the renin-angiotensin-aldosterone system (RAAS).</p>
        <p>All patients with STEMI should receive a beta-blocker in the absence of contraindications.<xref ref-type="bibr" rid="article-178.r12">[12]</xref><xref ref-type="bibr" rid="article-178.r7">[7]</xref> Absolute contraindications for beta-blockers in the acute phase include hypotension, acute heart failure, atrioventricular (AV) node block, or severe bradycardia. In the absence of contraindications, the decision comes to whether the patient needs to receive an immediate intravenous beta-blocker or an oral beta-blocker within 24 hours of diagnosis. In patients treated with fibrinolysis, early beta-blocker administration is the favored approach due to the observed reduction of acute malignant ventricular arrhythmias.<xref ref-type="bibr" rid="article-178.r42">[42]</xref><xref ref-type="bibr" rid="article-178.r43">[43]</xref><xref ref-type="bibr" rid="article-178.r44">[44]</xref> In patients undergoing primary PCI, evidence regarding early intravenous administration of beta-blocker and beneficial short and long-term effects is inconsistent; thus, due to the potential for adverse effects, routine use in such a manner is discouraged. Regardless, in every patient with STEMI, early beta-blocker therapy&#x000a0;may be considered in hemodynamically stable patients or those with hypertension, ongoing ischemia, or an arrhythmia that would benefit from early beta-blockade.<xref ref-type="bibr" rid="article-178.r12">[12]</xref><xref ref-type="bibr" rid="article-178.r7">[7]</xref>&#x000a0;A commonly used agent in patients undergoing fibrinolysis or primary PCI is metoprolol. Based on the CAPRICORN trial, patients who have transient or permanent left ventricular (LV) dysfunction after STEMI should preferably receive&#x000a0;carvedilol.<xref ref-type="bibr" rid="article-178.r45">[45]</xref></p>
        <p>Routine use of nitrates in patients with STEMI is not a strong recommendation unless used for angina relief.<xref ref-type="bibr" rid="article-178.r7">[7]</xref><xref ref-type="bibr" rid="article-178.r46">[46]</xref> Nitrates should be used in patients with STEMI during the acute phase for the treatment of chest pain due to ischemia, treatment of acute hypertension, or as a vasodilator for treatment of acute LV failure. Contraindications include the use of phosphodiesterase inhibitors in the past 48 hours, marked hypotension with systolic blood pressure less than 90 mmHg, and suspected right ventricular (RV) infarction. The agent used in the acute phase is nitroglycerin. The formulation is usually sublingual, but an intravenous formulation is an option in patients with waxing and waning chest pain and patients with acute LV failure.</p>
        <p>Analgesic treatment in patients with STEMI is important to reduce pain, which can lead to sympathetic hyperactivity, which further impairs myocardial oxygen demand. The recommended agent is intravenous morphine, and it should not be used routinely, but in those patients with severe chest pain, not responding to nitrates, and patients whose presentation is complicated by acute pulmonary edema. Side effects of bradycardia and hypotension require monitoring after morphine administration.</p>
        <p>Oxygen is indicated in patients in patients with hypoxemia evidenced by oxygen saturation less than 90% or arterial blood partial pressure of oxygen less than 60 mmHg.<xref ref-type="bibr" rid="article-178.r47">[47]</xref></p>
        <p>There is strong evidence that RAAS inhibitors, specifically angiotensin-converting enzyme (ACE) inhibitors, are beneficial in patients with STEMI.<xref ref-type="bibr" rid="article-178.r12">[12]</xref><xref ref-type="bibr" rid="article-178.r7">[7]</xref> These agents should be considered in all STEMI patients and unequivocally given to the ones with LV dysfunction, diabetes, or hypertension.<xref ref-type="bibr" rid="article-178.r12">[12]</xref><xref ref-type="bibr" rid="article-178.r7">[7]</xref> In patients who cannot tolerate ACE inhibitors, angiotensin receptor blockers (ARB) should be the alternative. These agents are usually started after 24 hours from admission or during index hospitalization and continued indefinitely in most patients. Mineralocorticoid receptor antagonists, such as eplerenone, have a well-established indication in patients with STEMI who have LV dysfunction and are already on a RAAS inhibitor and a beta-blocker.<xref ref-type="bibr" rid="article-178.r12">[12]</xref><xref ref-type="bibr" rid="article-178.r7">[7]</xref><xref ref-type="bibr" rid="article-178.r48">[48]</xref><xref ref-type="bibr" rid="article-178.r49">[49]</xref><xref ref-type="bibr" rid="article-178.r50">[50]</xref><xref ref-type="bibr" rid="article-178.r51">[51]</xref> Contraindications include acute renal failure, chronic renal failure with creatinine above 2.5 mg/dL, and hyperkalemia.</p>
        <p>Lipid-lowering agents are indicated in the treatment of STEMI.<xref ref-type="bibr" rid="article-178.r12">[12]</xref><xref ref-type="bibr" rid="article-178.r7">[7]</xref> The choice has to be high-intensity statin, with careful risk and benefit assessment in populations with increased risk of side effects (patients with liver failure, elderly above age 75 years, previous side effects). The goal of treatment is a reduction in low-density lipoprotein (LDL) by more than 50% from baseline. Thus it is important to check lipid levels in patients with STEMI on admission. The timing of initiation of statin treatment has been investigated in the SECURE-PCI trial and showed a trend toward a beneficial effect of early initiation of statin treatment in a subset of patients with STEMI, but data demonstrates no strong statistical significance.<xref ref-type="bibr" rid="article-178.r52">[52]</xref> Given the absence of harm in administering statin therapy early, it is reasonable to administer a statin as soon as possible following the diagnosis of STEMI. Agents preferably used in this setting are atorvastatin or rosuvastatin. Based on data from the IMPROVE-IT trial, ezetimibe should be a consideration in patients with intolerance or contraindication to statin treatment.<xref ref-type="bibr" rid="article-178.r53">[53]</xref> Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a group of medications that lower LDL. The two largest trials evaluating this group of medications were FOURIER and ODYSSEY trials. Both trials demonstrated a reduction in major adverse cardiovascular events when adding these agents to statin therapy.<xref ref-type="bibr" rid="article-178.r53">[53]</xref><xref ref-type="bibr" rid="article-178.r54">[54]</xref> The ODYSSEY trial involved patients who had ACS within 12 months of enrollment into the study. The major limitation of these agents remains cost. Regardless, they should be considered in patients on optimal statin therapy after STEMI, with the inability to achieve adequate reduction in LDL when assessed on outpatient follow-up.</p>
        <p>The principal difference in the management of UA/NSTEMI compared to STEMI is that the initial choice of treatment modality focuses on medical management with anti-ischemic, antiplatelet, anticoagulant and analgesic therapy, all with the&#x000a0;goal to minimize ischemia and prevent complications while simultaneously deciding on the timing and appropriateness of coronary angiography versus non-invasive testing and the type of revascularization strategy.</p>
        <p>The first decision to make is whether the patient needs a coronary angiography versus a form of non-invasive functional testing (such as myocardial perfusion imaging or stress echocardiography). Generally, patients with UA/NSTEMI can undergo an early invasive strategy or an ischemia-guided (i.e., selective invasive) approach. The early invasive strategy involves coronary angiography performed within 48 hours of presentation, and subsequent PCI, CABG, or medical therapy alone, depending on the characteristics of coronary anatomy. The ischemia-guided approach puts medical management as a priority, while coronary angiography would be the choice in patients exhibiting clinical signs and symptoms of ischemia (e.g., non-resolving chest pain, arrhythmic events, etc.), hemodynamic instability or has positive non-invasive testing. When making this initial modality choice, one should keep in mind that early invasive strategy is not recommended in two groups of patients: 1) patients who have extensive, severe comorbidities, where the risk of revascularization outweighs the benefit, and 2) patients who have chest pain, but a low clinical likelihood of ACS with negative cardiac biomarkers <xref ref-type="bibr" rid="article-178.r55">[55]</xref>. Literature suggests that early invasive strategy provides improved mortality and reduction in non-fatal MI.<xref ref-type="bibr" rid="article-178.r56">[56]</xref><xref ref-type="bibr" rid="article-178.r57">[57]</xref><xref ref-type="bibr" rid="article-178.r58">[58]</xref><xref ref-type="bibr" rid="article-178.r59">[59]</xref><xref ref-type="bibr" rid="article-178.r60">[60]</xref> Given the available evidence, clinicians should pursue an early invasive strategy in patients with NSTEMI in the absence of contraindications. Upon making the decision for an early invasive strategy, it is critical to identify certain higher-risk features of the patient that would warrant a coronary angiography sooner rather than later.<xref ref-type="bibr" rid="article-178.r11">[11]</xref> These include cardiogenic shock, recurrent or ongoing chest pain refractory to medical treatment, mechanical complications of MI, acute heart failure, prior CABG, prior PCI within six months of presentation with the clinical suspicion of in-stent restenosis or patients with a GRACE score greater than 140.<xref ref-type="bibr" rid="article-178.r11">[11]</xref></p>
        <p>Antiplatelet agents have a well-established benefit in UA/NSTEMI patients.<xref ref-type="bibr" rid="article-178.r61">[61]</xref><xref ref-type="bibr" rid="article-178.r62">[62]</xref><xref ref-type="bibr" rid="article-178.r63">[63]</xref> After the diagnosis of UA/NSTEMI has been made or highly suspected, all patients should receive aspirin and subsequently continued on a daily maintenance dose.<xref ref-type="bibr" rid="article-178.r21">[21]</xref><xref ref-type="bibr" rid="article-178.r64">[64]</xref>&#x000a0;In addition to aspirin, all patients with UA/NSTEMI should receive therapy with a P2Y12 inhibitor.<xref ref-type="bibr" rid="article-178.r65">[65]</xref><xref ref-type="bibr" rid="article-178.r66">[66]</xref><xref ref-type="bibr" rid="article-178.r11">[11]</xref> The choice and timing of administration of the second antiplatelet agent will depend on whether early invasive strategy or ischemia-guided strategy was the choice and whether PCI, CABG, or medical management is the chosen option. PLATO and TRITON TIMI-38 trials have demonstrated more potent inhibition of platelets by ticagrelor and prasugrel when compared to clopidogrel, respectively. Thus for most patients, ticagrelor or prasugrel are the first choices of the second antiplatelet agents, but bearing in mind certain important caveats. In TRITON TIMI 38 trial, prasugrel has been shown to have less efficacy and increased risk of bleeding in patients who were over 75 years old, had a body weight less than 65 kg or had a history of a transient ischemic attack (TIA) or stroke.<xref ref-type="bibr" rid="article-178.r23">[23]</xref> These patients should not receive prasugrel. Also, patients who will not undergo PCI after coronary angiography should not receive prasugrel.<xref ref-type="bibr" rid="article-178.r11">[11]</xref> PRAGUE-18 trial demonstrated no difference in efficacy and safety between prasugrel and clopidogrel in patients with ACS undergoing PCI.<xref ref-type="bibr" rid="article-178.r24">[24]</xref> It is important to note that the PLATO trial included a subset of patients who were undergoing PCI, CABG, or treated medically.<xref ref-type="bibr" rid="article-178.r22">[22]</xref>&#x000a0;Based on the results&#x000a0;of&#x000a0;the PLATO trial, it is recommended&#x000a0;to use&#x000a0;81 mg&#x000a0;aspirin dosing for long-term maintenance&#x000a0;when using ticagrelor as the second P2Y12 agent. Higher dosing of aspirin&#x000a0;(162 to 325 mg) may attenuate&#x000a0;the efficacy of ticagrelor. Clopidogrel should be considered as initial therapy if there is a concern regarding cost and access to ticagrelor or prasugrel, or the patient is at increased risk of bleeding. In the subset of patients who are undergoing ischemia-guided strategy, the initial choice of second antiplatelet agent should be ticagrelor, with clopidogrel considered for the same reason as for patients undergoing early-invasive strategy.<xref ref-type="bibr" rid="article-178.r22">[22]</xref> Prasugrel should be avoided in this group of patients because the TRILOGY ACS trial demonstrated that prasugrel is associated with a slightly increased risk of bleeding when compared to clopidogrel in patients who are not undergoing primary PCI.<xref ref-type="bibr" rid="article-178.r26">[26]</xref> This data makes ticagrelor a safer option in patients undergoing an ischemia-guided approach when it is still unknown whether PCI will take place or not. Regardless of the initial strategy, a certain subset of patients with UA/NSTEMI will require CABG as a form of revascularization after defining coronary anatomy. These patients will, by that time, usually receive both aspirin and a P2Y12 inhibitor. The recommendation is that clopidogrel and ticagrelor should be held for five days before surgery, while prasugrel should be held seven days before the surgery.<xref ref-type="bibr" rid="article-178.r11">[11]</xref><xref ref-type="bibr" rid="article-178.r55">[55]</xref><xref ref-type="bibr" rid="article-178.r67">[67]</xref> Aspirin should not be interrupted for CABG.<xref ref-type="bibr" rid="article-178.r11">[11]</xref><xref ref-type="bibr" rid="article-178.r55">[55]</xref><xref ref-type="bibr" rid="article-178.r67">[67]</xref> Consideration to stop aspirin 3 to 5 days preoperatively is an option in patients with a significant risk of bleeding who are refusing blood transfusions.<xref ref-type="bibr" rid="article-178.r11">[11]</xref> Ultimately, unstable patients with UA/NSTEMI who have anatomy more suitable for CABG, have evidence of ongoing ischemia or hemodynamic instability should be considered for emergent CABG regardless of antiplatelet therapy.</p>
        <p>Given the complexities in predicting how the revascularization strategy will change, depending on the clinical scenario and coronary anatomy, the timing of the P2Y12 inhibitor administration has been debated due to concern for potentially delaying CABG if such type of revascularization is needed. Based on the current European and American guidelines, both recommend that the P2Y12 inhibitor is administered as promptly as possible after the diagnosis of UA/NSTEMI.<xref ref-type="bibr" rid="article-178.r11">[11]</xref><xref ref-type="bibr" rid="article-178.r55">[55]</xref><xref ref-type="bibr" rid="article-178.r67">[67]</xref> In real-world practice, it is not unusual that P2Y12 inhibitor administration occurs in selected individuals&#x000a0;at the time of coronary angiography with the identification of coronary anatomy and the formulation of a revascularization plan. Although major trials that evaluated the use of ticagrelor, prasugrel, and clopidogrel in ACS patients did include patients where a P2Y12 inhibitor was administered during coronary angiography and sometimes even after, current guidelines do not recommend this practice, and it remains upon the discretion of the interventional cardiologist on a case-by-case basis. It would be&#x000a0;reasonable&#x000a0;to say that P2Y12 administration&#x000a0;may be&#x000a0;delayed if the clinical&#x000a0;suspicion for&#x000a0;underlying&#x000a0;multivessel disease&#x000a0;and the need&#x000a0;for surgical revascularization remains high.&#x000a0;</p>
        <p>Finally, there is limited use of GpIIb/IIIa inhibitors in patients with UA/NSTEMI.<xref ref-type="bibr" rid="article-178.r68">[68]</xref><xref ref-type="bibr" rid="article-178.r69">[69]</xref> These involve patients who are very likely to undergo CABG (e.g., the ones with already known high-risk coronary anatomy, high-risk patients with hemodynamic instability and ongoing ischemia), where GpIIb/IIIa inhibitor can be used before administering P2Y12 inhibitor until defining a clear operative plan. The other group where such therapy should be a consideration includes patients with thrombotic complications during coronary angiography.<xref ref-type="bibr" rid="article-178.r68">[68]</xref><xref ref-type="bibr" rid="article-178.r69">[69]</xref><xref ref-type="bibr" rid="article-178.r70">[70]</xref></p>
        <p>In the absence of absolute contraindication, anticoagulation is indicated in all patients with UA/NSTEMI once the diagnosis is made.<xref ref-type="bibr" rid="article-178.r11">[11]</xref><xref ref-type="bibr" rid="article-178.r55">[55]</xref><xref ref-type="bibr" rid="article-178.r71">[71]</xref> Enoxaparin, UFH, and fondaparinux&#x000a0;are listed as&#x000a0;class I of recommendation for this purpose.<xref ref-type="bibr" rid="article-178.r11">[11]</xref><xref ref-type="bibr" rid="article-178.r55">[55]</xref><xref ref-type="bibr" rid="article-178.r67">[67]</xref> Enoxaparin and fondaparinux should be avoided in patients with severe renal failure. Data from the SYNERGY trial demonstrated the non-inferiority of enoxaparin when compared to UFH in terms of efficacy, with the expense of a modest increase in bleeding risk.<xref ref-type="bibr" rid="article-178.r72">[72]</xref><xref ref-type="bibr" rid="article-178.r73">[73]</xref>&#x000a0;On the other hand, a meta-analysis published eight years after the SYNERGY trial reported a superior effect of enoxaparin when compared to UFH in reducing mortality and bleeding outcomes during PCI in patients with ACS.<xref ref-type="bibr" rid="article-178.r37">[37]</xref> The benefit was observed mostly in patients with STEMI. OASIS-5 study has demonstrated non-inferiority in the efficacy of fondaparinux compared to enoxaparin, with a better bleeding risk profile.<xref ref-type="bibr" rid="article-178.r74">[74]</xref> An important caveat was an increased risk of catheter-related thrombosis during PCI, which was successfully mitigated by intraprocedural UFH administration.<xref ref-type="bibr" rid="article-178.r74">[74]</xref><xref ref-type="bibr" rid="article-178.r75">[75]</xref>&#x000a0;Based on these observations, a reasonable approach would be that in patients undergoing early invasive strategy, where PCI is expected, the anticoagulant of choice should be UFH, while enoxaparin could be an option in the absence of bleeding risk and renal failure. Fondaparinux should be considered in patients with higher bleeding risk in the absence of advanced renal failure but would mandate intraprocedural UFH administration&#x000a0;to prevent&#x000a0;intra-procedural catheter thrombosis. In patients managed by ischemia-guided strategy and PCI is unlikely to happen, fondaparinux offers optimal safety profile, while observations from ESSENCE and TIMI 11B trial suggest that enoxaparin in this clinical scenario should be favored when compared to UFH.<xref ref-type="bibr" rid="article-178.r76">[76]</xref><xref ref-type="bibr" rid="article-178.r77">[77]</xref> Bivalirudin is recommended as an anticoagulant agent in patients with UA/NSTEMI who have heparin-induced thrombocytopenia. Otherwise, bivalirudin offers a questionable benefit to a very small group of patients. Those patients would have characteristics that favor a strong inclination to add GpIIb/IIIa inhibitors and, at the same time, would have to be at increased risk of bleeding. In that situation, given non-inferiority in ischemic risk and lower incidence of bleeding with bivalirudin monotherapy compared to LMWH or UFH+GpIIb/IIIa, bivalirudin would be a choice.<xref ref-type="bibr" rid="article-178.r68">[68]</xref> Anticoagulation in the acute phase of UA/NSTEMI treatment is discontinued after revascularization, or in the case when no revascularization is performed, discontinuation is performed&#x000a0;after at least 48 hours.<xref ref-type="bibr" rid="article-178.r11">[11]</xref><xref ref-type="bibr" rid="article-178.r55">[55]</xref><xref ref-type="bibr" rid="article-178.r71">[71]</xref></p>
        <p>Symptomatic therapy with nitrates, morphine, and beta-blockers in the acute phase of UA/NSTEMI, resembles&#x000a0;that of&#x000a0;patients with STEMI, as described above. High-intensity statin therapy is the recommendation for all patients with UA/NSTEMI and should be initiated as early as possible after admission to the hospital.<xref ref-type="bibr" rid="article-178.r11">[11]</xref><xref ref-type="bibr" rid="article-178.r78">[78]</xref><xref ref-type="bibr" rid="article-178.r79">[79]</xref><xref ref-type="bibr" rid="article-178.r80">[80]</xref> ACE inhibitors should be started as a long-term therapy after UA/NSTEMI in patients with LV dysfunction, hypertension, or diabetes mellitus type 2, while ARBs should be the choice in the case where ACE inhibitor tolerance is an issue.<xref ref-type="bibr" rid="article-178.r81">[81]</xref><xref ref-type="bibr" rid="article-178.r82">[82]</xref><xref ref-type="bibr" rid="article-178.r83">[83]</xref><xref ref-type="bibr" rid="article-178.r84">[84]</xref><xref ref-type="bibr" rid="article-178.r85">[85]</xref> Beta-blockers have well-known, proven efficacy in patients with UA/NSTEMI who have LV dysfunction.<xref ref-type="bibr" rid="article-178.r45">[45]</xref><xref ref-type="bibr" rid="article-178.r86">[86]</xref><xref ref-type="bibr" rid="article-178.r87">[87]</xref><xref ref-type="bibr" rid="article-178.r88">[88]</xref><xref ref-type="bibr" rid="article-178.r89">[89]</xref> Even though beta-blockers dosing is a long-term therapy for all patients with UA/NSTEMI, there have been no contemporary randomized controlled trials to assess its use in patients without LV dysfunction.<xref ref-type="bibr" rid="article-178.r11">[11]</xref> Long-term treatment with mineralocorticoid receptor antagonists&#x000a0;(such as eplerenone or spironolactone) is recommended in patients with UA/NSTEMI and LVEF less than 40% and heart failure or diabetes.<xref ref-type="bibr" rid="article-178.r48">[48]</xref><xref ref-type="bibr" rid="article-178.r49">[49]</xref><xref ref-type="bibr" rid="article-178.r50">[50]</xref></p>
        <p>Dual antiplatelet therapy (DAPT) in patients after ACS should ideally be continued for 12 months, regardless if they underwent fibrinolysis, CABG, or PCI and irrespective of what type of stent is placed.<xref ref-type="bibr" rid="article-178.r90">[90]</xref> If patients on DAPT develop a high bleeding risk or sustain significant bleeding, discontinuation of P2Y12 inhibitor after six months is reasonable, and the recent guidelines support this approach.</p>
      </sec>
      <sec id="article-178.s4" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>One of the significant issues in the management of patients who had ACS is the optimal strategy to balance ischemic risk and bleeding risk in patients who require long-term anticoagulation due to another specific indication, as these patients already require antiplatelet therapy post-ACS. This type of treatment has the name triple therapy. In the most recent ACC/AHA guideline on UA/NSTEMI, the recommendation is that patients who had ACS and underwent PCI should receive triple therapy, but with making every effort to minimize the duration to limit the risk of bleeding.<xref ref-type="bibr" rid="article-178.r55">[55]</xref> Literature reports unequivocally increased risk of bleeding in patients who are on triple therapy when compared to DAPT or single antiplatelet agent.<xref ref-type="bibr" rid="article-178.r55">[55]</xref><xref ref-type="bibr" rid="article-178.r91">[91]</xref><xref ref-type="bibr" rid="article-178.r92">[92]</xref> Several strategies have been proposed to mitigate those risks. These include the use of clinical calculators such as HAS-BLED to assess bleeding risk, evaluating the appropriateness of indication for anticoagulation, targeting the international normalized ratio (INR) to 2 to 2.5 when using warfarin, the use of clopidogrel instead of more potent P2Y12 inhibitors, and the use of proton pump inhibitors in patients with a prior history or at risk of gastrointestinal bleeding.<xref ref-type="bibr" rid="article-178.r90">[90]</xref> The most recent guidelines for the management of ACS recommend that triple therapy continues for six months following PCI in patients with lower bleeding risk, assessed by HAS-BLED score is equal to or less than 2, followed by&#x000a0;an&#x000a0;oral anticoagulant (OAC)&#x000a0;and clopidogrel or aspirin for the remaining 6 months.<xref ref-type="bibr" rid="article-178.r7">[7]</xref><xref ref-type="bibr" rid="article-178.r11">[11]</xref><xref ref-type="bibr" rid="article-178.r55">[55]</xref> In patients with HAS-BLED score of 3 and above, the recommendation is that triple therapy should be administered for one month, followed by an oral anticoagulant (OAC) and clopidogrel or aspirin for the total duration of 12 months. The choice of OAC involves a vitamin K antagonist (VKA) or a non-VKA novel oral anticoagulant (NOAC), based on the patient's preference and other socioeconomic factors. The decision between aspirin and clopidogrel during the period of treatment with OAC and one antiplatelet agent depends on the balance of ischemic risks such as complex coronary stenting, left main disease, bifurcation lesions, patients with diabetes, and bleeding risks such as a history of major bleeding and predisposition for future bleeding events. After 12 months of the described treatment, the guidelines recommend that OAC should be continued as a monotherapy indefinitely for the original indication.<xref ref-type="bibr" rid="article-178.r7">[7]</xref><xref ref-type="bibr" rid="article-178.r11">[11]</xref><xref ref-type="bibr" rid="article-178.r55">[55]</xref> In patients with ACS who did not undergo revascularization or have undergone CABG, the recommendation is that dual therapy involving OAC and aspirin or clopidogrel should continue for 12 months, and after completing that time, OAC should remain in place. Regardless of the type of revascularization, patients with high ischemic risk may continue OAC and aspirin beyond the 12-month time frame. Several recent trial results have disputed the concept of triple therapy and examined the effect of OAC along with P2Y12 inhibitor in patients with ACS who are undergoing PCI.<xref ref-type="bibr" rid="article-178.r93">[93]</xref><xref ref-type="bibr" rid="article-178.r94">[94]</xref><xref ref-type="bibr" rid="article-178.r95">[95]</xref><xref ref-type="bibr" rid="article-178.r96">[96]</xref> WOEST, PIONEER-AF, RE-DUAL<xref ref-type="bibr" rid="article-178.r96">[96]</xref>, and AUGUSTUS trials have examined the efficacy and safety of&#x000a0;warfarin, rivaroxaban, dabigatran, and apixaban, respectively, in conjunction with clopidogrel for treatment of patients with ACS who underwent PCI, compared to treatment with triple therapy.<xref ref-type="bibr" rid="article-178.r93">[93]</xref><xref ref-type="bibr" rid="article-178.r95">[95]</xref><xref ref-type="bibr" rid="article-178.r96">[96]</xref><xref ref-type="bibr" rid="article-178.r97">[97]</xref> Based on the reported results, it appears that dual therapy with an anticoagulant agent and P2Y12 inhibitor, when compared to triple therapy, significantly decreases the bleeding risk, while ischemic and thromboembolic risk remains unchanged. Based on these studies, new practice-changing guidelines are warranted, and the data requires interpretation for safe use in clinical practice. The ongoing ENTRUST-PCI study (NCT02866175) will provide data on edoxaban in this type of clinical scenario. It is worth noting that patients receiving anticoagulation for mechanical valve should exclusively be on warfarin, while the antiplatelet regimen strategy is essentially the same as described above.</p>
      </sec>
      <sec id="article-178.s5" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Special attention needs to be devoted to a particular subset of patients with cardiogenic shock following ACS. Cardiogenic shock as a complication of ACS is most commonly the consequence of LV failure, while other causes include mechanical complications such as ventricular septal defect, papillary muscle rupture, and RV failure.<xref ref-type="bibr" rid="article-178.r98">[98]</xref> In-hospital mortality rates, once cardiogenic shock occurs, are 40 to 60%, and prompt revascularization is one of the interventions that potentially can provide benefit.<xref ref-type="bibr" rid="article-178.r98">[98]</xref><xref ref-type="bibr" rid="article-178.r99">[99]</xref> Such patients require immediate attention and rapid institution of inotropes or vasopressors, mechanical circulatory support, and an effective revascularization strategy.<xref ref-type="bibr" rid="article-178.r100">[100]</xref> Contemporary trials suggest that revascularization should take place as early as possible, and if PCI is the chosen strategy, the culprit vessel should be revascularized as opposed to multivessel PCI.<xref ref-type="bibr" rid="article-178.r101">[101]</xref><xref ref-type="bibr" rid="article-178.r102">[102]</xref> Patients with RV infarction can have a clinical presentation of cardiogenic shock. In such patients, special care should be taken to avoid worsening hypotension due to medications such as nitrates, morphine, and diuretics (that&#x000a0;may be otherwise&#x000a0;routinely&#x000a0;used in patients with&#x000a0;myocardial infarction and LV dysfunction). Patients with RV infarction benefit from volume expansion that will increase RV preload and subsequent cardiac output.<xref ref-type="bibr" rid="article-178.r103">[103]</xref></p>
      </sec>
      <sec id="article-178.s6" sec-type="Other Issues">
        <title>Other Issues</title>
        <p>There are several subgroups of patients with UA/NSTEMI that are at higher risk of adverse outcomes. Those include patients aged 75 or older, women, diabetes mellitus (DM), and chronic kidney disease (CKD).<xref ref-type="bibr" rid="article-178.r11">[11]</xref> Patients older than 75 years have a higher incidence and prevalence of adverse outcomes, increased risk of bleeding, and are more likely to present with atypical symptoms.<xref ref-type="bibr" rid="article-178.r6">[6]</xref><xref ref-type="bibr" rid="article-178.r104">[104]</xref><xref ref-type="bibr" rid="article-178.r105">[105]</xref><xref ref-type="bibr" rid="article-178.r106">[106]</xref> Practical suggestions to decrease the risk of bleeding in the elderly include the use of low-dose aspirin, avoidance of prasugrel, consideration for the use of bivalirudin as an anticoagulant, and avoidance of abciximab if there is a need for the use of GpIIb/IIIa inhibitor.<xref ref-type="bibr" rid="article-178.r107">[107]</xref> It merits noting that in the absence of comorbidities that are a potential contraindication for revascularization, advanced age alone should not determine that the patient does not need early invasive strategy or revascularization.<xref ref-type="bibr" rid="article-178.r55">[55]</xref> Multiple studies have shown that women, compared to men, present with atypical symptoms, tend to have more comorbidities, and have a lower likelihood of being referred for coronary angiography.<xref ref-type="bibr" rid="article-178.r60">[60]</xref><xref ref-type="bibr" rid="article-178.r105">[105]</xref><xref ref-type="bibr" rid="article-178.r108">[108]</xref> These findings warrant implementation for raising awareness of cardiovascular risk in women and adherence to the guidelines for the treatment of UA/NSTEMI regardless of sex.<xref ref-type="bibr" rid="article-178.r109">[109]</xref> Given worse outcomes in patients with DM who present with UA/NSTEMI,<xref ref-type="bibr" rid="article-178.r110">[110]</xref>&#x000a0;it is important to note that certain choices in treatment modality must merit consideration. Limited data show the benefit of more potent antiplatelet agents, such as prasugrel&#x000a0;<xref ref-type="bibr" rid="article-178.r111">[111]</xref>, along with favoring early invasive strategy in patients with DM, and preference of CABG compared to PCI in diabetic patients with complex coronary artery disease.<xref ref-type="bibr" rid="article-178.r11">[11]</xref><xref ref-type="bibr" rid="article-178.r112">[112]</xref> Patients with CKD who present with UA/NSTEMI are at increased risk of recurrent ischemic events, stent thrombosis, and post-PCI ischemic events.<xref ref-type="bibr" rid="article-178.r113">[113]</xref><xref ref-type="bibr" rid="article-178.r114">[114]</xref><xref ref-type="bibr" rid="article-178.r115">[115]</xref> Patients with advanced CKD stage IV or V usually get excluded from most of the clinical studies. A meta-analysis involving UA/NSTEMI patients with CKD has demonstrated favorable outcomes with an early invasive strategy.<xref ref-type="bibr" rid="article-178.r59">[59]</xref> Data suggest that CABG is the preferred option of revascularization in patients with CKD who have multivessel CAD and acceptable surgical risk, while if PCI is selected, DES is preferable over BMS.<xref ref-type="bibr" rid="article-178.r11">[11]</xref></p>
      </sec>
      <sec id="article-178.s7" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Many interventions and treatments have been proven so far to improve outcomes in patients with ACS. Still, given the emerging new evidence, heterogeneity in the population of patients with ACS, and complexity in optimal decision-making in managing these patients, a robust interprofessional and streamlined system is necessary to keep improving outcomes. The highly coordinated care of&#x000a0;patients with ACS, especially those with STEMI, starts early, with the first contact with emergency medical services (EMS) or the first contact with the emergency department. It is crucial that regardless of the type of initial medical contact, an electrocardiogram (ECG) needs to take place in less than 10 minutes, and the initial diagnosis is made.<xref ref-type="bibr" rid="article-178.r7">[7]</xref><xref ref-type="bibr" rid="article-178.r116">[116]</xref><xref ref-type="bibr" rid="article-178.r117">[117]</xref> If a STEMI is suspected, it is necessary to provide ECG monitoring with the capacity of defibrillation.<xref ref-type="bibr" rid="article-178.r7">[7]</xref><xref ref-type="bibr" rid="article-178.r118">[118]</xref><xref ref-type="bibr" rid="article-178.r119">[119]</xref> Given these requirements, success in outcomes will depend on adequate prehospital care resources and prompt access to the healthcare facility. It requires efficient transportation, trained personnel, availability of therapeutics, and optimal communication with the healthcare providers in the corresponding hospital, enabling early activation of the cardiac catheterization lab.<xref ref-type="bibr" rid="article-178.r120">[120]</xref><xref ref-type="bibr" rid="article-178.r121">[121]</xref><xref ref-type="bibr" rid="article-178.r122">[122]</xref><xref ref-type="bibr" rid="article-178.r123">[123]</xref> Given the proven benefit of timely evaluation of patients with STEMI, avoiding treatment delays is necessary at all costs. There should be a system with meticulous tracking of target times for the institution of quality improvement. It is essential to raise awareness of the symptoms of ACS is raised in the general population for the avoidance of patient-related treatment delays.<xref ref-type="bibr" rid="article-178.r124">[124]</xref><xref ref-type="bibr" rid="article-178.r125">[125]</xref><xref ref-type="bibr" rid="article-178.r126">[126]</xref></p>
        <p>It is essential to create a geographic area of responsibility to transport patients to a PCI-capable center in a timely fashion, where the cardiac catheterization lab is available 24 hours a day, seven days per week, and where healthcare personnel has clear written protocols that facilitate risk stratification and management.<xref ref-type="bibr" rid="article-178.r127">[127]</xref><xref ref-type="bibr" rid="article-178.r128">[128]</xref><xref ref-type="bibr" rid="article-178.r129">[129]</xref><xref ref-type="bibr" rid="article-178.r130">[130]</xref> In geographic areas where timely transport to a PCI-capable facility is not possible, there is a need for a clear protocol for prehospital or early hospital fibrinolysis.<xref ref-type="bibr" rid="article-178.r131">[131]</xref><xref ref-type="bibr" rid="article-178.r132">[132]</xref><xref ref-type="bibr" rid="article-178.r133">[133]</xref> The care coordination continues upon patient admission in the hospital, and it is necessary that hospitals provide infrastructure in the form of coronary care units (CCU) or intensive care units (ICU), along with the units that have the capability of continuous monitoring and specialized care for patients with ACS.<xref ref-type="bibr" rid="article-178.r134">[134]</xref> A coordinated discharge of the patient is of paramount importance after the acute phase of treatment, medical stabilization, and optimal hospital stay. Apart from the medication reconciliation and confirmation that the patient will be able to receive the medications, interventions including smoking cessation, nutrition education, weight control, and exercise-based cardiac rehabilitation are strongly advised.<xref ref-type="bibr" rid="article-178.r135">[135]</xref><xref ref-type="bibr" rid="article-178.r136">[136]</xref><xref ref-type="bibr" rid="article-178.r137">[137]</xref> To reduce the gap between the ideal care and the real-world care of patients with ACS,<xref ref-type="bibr" rid="article-178.r138">[138]</xref><xref ref-type="bibr" rid="article-178.r139">[139]</xref> establishing quality indicators is recommended with the goal to serve as a foundation for quality improvement interventions.<xref ref-type="bibr" rid="article-178.r140">[140]</xref></p>
        <p>ACS therapy modality selection requires an interprofessional team approach, including physicians, specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results. [Level 5]</p>
      </sec>
      <sec id="article-178.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=178&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=178">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/178/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=178">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-178.s9">
        <title>References</title>
        <ref id="article-178.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Acute coronary syndromes: diagnosis and management, part I.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>84</volume>
            <issue>10</issue>
            <fpage>917</fpage>
            <page-range>917-38</page-range>
            <pub-id pub-id-type="pmid">19797781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Libby</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of acute coronary syndromes and their implications for therapy.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>May</month>
            <day>23</day>
            <volume>368</volume>
            <issue>21</issue>
            <fpage>2004</fpage>
            <page-range>2004-13</page-range>
            <pub-id pub-id-type="pmid">23697515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Makki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Girotra</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Acute coronary syndrome.</article-title>
            <source>J Intensive Care Med</source>
            <year>2015</year>
            <month>May</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>186</fpage>
            <page-range>186-200</page-range>
            <pub-id pub-id-type="pmid">24047692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crea</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Libby</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision Treatment.</article-title>
            <source>Circulation</source>
            <year>2017</year>
            <month>Sep</month>
            <day>19</day>
            <volume>136</volume>
            <issue>12</issue>
            <fpage>1155</fpage>
            <page-range>1155-1166</page-range>
            <pub-id pub-id-type="pmid">28923905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Ascheim</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>de Lemos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ettinger</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fesmire</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Linderbaum</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Ornato</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Tamis-Holland</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tommaso</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>DX</given-names>
              </name>
            </person-group>
            <article-title>2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2013</year>
            <month>Jan</month>
            <day>29</day>
            <volume>61</volume>
            <issue>4</issue>
            <fpage>e78</fpage>
            <page-range>e78-e140</page-range>
            <pub-id pub-id-type="pmid">23256914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mozaffarian</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Go</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Arnett</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Blaha</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Cushman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Ferranti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Despr&#x000e9;s</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Fullerton</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Huffman</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Judd</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kissela</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Lackland</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Lichtman</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lisabeth</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mackey</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Matchar</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Mohler</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Moy</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mussolino</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Nasir</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Neumar</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Nichol</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Palaniappan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pandey</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Reeves</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Sorlie</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Towfighi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Turan</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Willey</surname>
                <given-names>JZ</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>MB</given-names>
              </name>
              <collab>American Heart Association Statistics Committee and Stroke Statistics Subcommittee</collab>
            </person-group>
            <article-title>Heart disease and stroke statistics--2015 update: a report from the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2015</year>
            <month>Jan</month>
            <day>27</day>
            <volume>131</volume>
            <issue>4</issue>
            <fpage>e29</fpage>
            <page-range>e29-322</page-range>
            <pub-id pub-id-type="pmid">25520374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ibanez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Agewall</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Antunes</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bucciarelli-Ducci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bueno</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Caforio</surname>
                <given-names>ALP</given-names>
              </name>
              <name>
                <surname>Crea</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Goudevenos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Halvorsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hindricks</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kastrati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lenzen</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Prescott</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Roffi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Valgimigli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Varenhorst</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vranckx</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Widimsk&#x000fd;</surname>
                <given-names>P</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).</article-title>
            <source>Eur Heart J</source>
            <year>2018</year>
            <month>Jan</month>
            <day>07</day>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>119</fpage>
            <page-range>119-177</page-range>
            <pub-id pub-id-type="pmid">28886621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rogers</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Frederick</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Stoehr</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Canto</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Ornato</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Pollack</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Gore</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Chandra-Strobos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006.</article-title>
            <source>Am Heart J</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>156</volume>
            <issue>6</issue>
            <fpage>1026</fpage>
            <page-range>1026-34</page-range>
            <pub-id pub-id-type="pmid">19032996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fokkema</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Albertsson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Akerblom</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Calais</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>de Smet</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Sj&#x000f6;gren</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Thorvinger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lagerqvist</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Population trends in percutaneous coronary intervention: 20-year results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2013</year>
            <month>Mar</month>
            <day>26</day>
            <volume>61</volume>
            <issue>12</issue>
            <fpage>1222</fpage>
            <page-range>1222-30</page-range>
            <pub-id pub-id-type="pmid">23500325</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pedersen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Butrymovich</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kelb&#x000e6;k</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wachtell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Helqvist</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kastrup</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Holmvang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Clemmensen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Engstr&#x000f8;m</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Grande</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saunam&#x000e4;ki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>J&#x000f8;rgensen</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Short- and long-term cause of death in patients treated with primary PCI for STEMI.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2014</year>
            <month>Nov</month>
            <day>18-25</day>
            <volume>64</volume>
            <issue>20</issue>
            <fpage>2101</fpage>
            <page-range>2101-8</page-range>
            <pub-id pub-id-type="pmid">25457398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roffi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patrono</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Collet</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Valgimigli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Andreotti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bax</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Borger</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Brotons</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Gencer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hasenfuss</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lancellotti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Landmesser</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Mehilli</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Storey</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Windecker</surname>
                <given-names>S</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).</article-title>
            <source>Eur Heart J</source>
            <year>2016</year>
            <month>Jan</month>
            <day>14</day>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>267</fpage>
            <page-range>267-315</page-range>
            <pub-id pub-id-type="pmid">26320110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Ascheim</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>de Lemos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ettinger</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fesmire</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Linderbaum</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Ornato</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Tamis-Holland</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tommaso</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>DX</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Brindis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Creager</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>DeMets</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guyton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hochman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <collab>American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</collab>
            </person-group>
            <article-title>2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2013</year>
            <month>Jan</month>
            <day>29</day>
            <volume>127</volume>
            <issue>4</issue>
            <fpage>e362</fpage>
            <page-range>e362-425</page-range>
            <pub-id pub-id-type="pmid">23247304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gersh</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future?</article-title>
            <source>JAMA</source>
            <year>2005</year>
            <month>Feb</month>
            <day>23</day>
            <volume>293</volume>
            <issue>8</issue>
            <fpage>979</fpage>
            <page-range>979-86</page-range>
            <pub-id pub-id-type="pmid">15728169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonnefoy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Boutitie</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dubien</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Lapostolle</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Roncalli</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dissait</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vanzetto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Leizorowicz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kirkorian</surname>
                <given-names>G</given-names>
              </name>
              <collab>CAPTIM Investigators</collab>
              <name>
                <surname>Mercier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McFadden</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Touboul</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up.</article-title>
            <source>Eur Heart J</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>30</volume>
            <issue>13</issue>
            <fpage>1598</fpage>
            <page-range>1598-606</page-range>
            <pub-id pub-id-type="pmid">19429632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armstrong</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Gershlick</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Danays</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sulimov</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rosell Ortiz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ostojic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Welsh</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Nanas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Arntz</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Halvorsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Grajek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fresco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bluhmki</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Regelin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vandenberghe</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bogaerts</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Van de Werf</surname>
                <given-names>F</given-names>
              </name>
              <collab>STREAM Investigative Team</collab>
            </person-group>
            <article-title>Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Apr</month>
            <day>11</day>
            <volume>368</volume>
            <issue>15</issue>
            <fpage>1379</fpage>
            <page-range>1379-87</page-range>
            <pub-id pub-id-type="pmid">23473396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lassen</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>B&#x000f8;tker</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Terkelsen</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Timely and optimal treatment of patients with STEMI.</article-title>
            <source>Nat Rev Cardiol</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-8</page-range>
            <pub-id pub-id-type="pmid">23165072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <article-title>Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group.</article-title>
            <source>Lancet</source>
            <year>1994</year>
            <month>Feb</month>
            <day>05</day>
            <volume>343</volume>
            <issue>8893</issue>
            <fpage>311</fpage>
            <page-range>311-22</page-range>
            <pub-id pub-id-type="pmid">7905143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van de Werf</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The history of coronary reperfusion.</article-title>
            <source>Eur Heart J</source>
            <year>2014</year>
            <month>Oct</month>
            <day>01</day>
            <volume>35</volume>
            <issue>37</issue>
            <fpage>2510</fpage>
            <page-range>2510-5</page-range>
            <pub-id pub-id-type="pmid">25024409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halvorsen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The role of fibrinolysis in the era of primary percutaneous coronary intervention.</article-title>
            <source>Thromb Haemost</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>105</volume>
            <issue>3</issue>
            <fpage>390</fpage>
            <page-range>390-5</page-range>
            <pub-id pub-id-type="pmid">21136014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baigent</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Appleby</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Parish</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sleight</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.</article-title>
            <source>BMJ</source>
            <year>1998</year>
            <month>May</month>
            <day>02</day>
            <volume>316</volume>
            <issue>7141</issue>
            <fpage>1337</fpage>
            <page-range>1337-43</page-range>
            <pub-id pub-id-type="pmid">9563981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehta</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Tanguay</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Eikelboom</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Jolly</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Joyner</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Faxon</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Rupprecht</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Budaj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Avezum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Widimsky</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Bassand</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Montalescot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Macaya</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Di Pasquale</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Niemela</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ajani</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Chrolavicius</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
              <collab>CURRENT-OASIS 7 trial investigators</collab>
            </person-group>
            <article-title>Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.</article-title>
            <source>Lancet</source>
            <year>2010</year>
            <month>Oct</month>
            <day>09</day>
            <volume>376</volume>
            <issue>9748</issue>
            <fpage>1233</fpage>
            <page-range>1233-43</page-range>
            <pub-id pub-id-type="pmid">20817281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallentin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Budaj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Emanuelsson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Held</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Horrow</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Husted</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Katus</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Scirica</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Skene</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Storey</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
              <collab>PLATO Investigators</collab>
              <name>
                <surname>Freij</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thors&#x000e9;n</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Ticagrelor versus clopidogrel in patients with acute coronary syndromes.</article-title>
            <source>N Engl J Med</source>
            <year>2009</year>
            <month>Sep</month>
            <day>10</day>
            <volume>361</volume>
            <issue>11</issue>
            <fpage>1045</fpage>
            <page-range>1045-57</page-range>
            <pub-id pub-id-type="pmid">19717846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montalescot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wiviott</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>McCabe</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Antman</surname>
                <given-names>EM</given-names>
              </name>
              <collab>TRITON-TIMI 38 investigators</collab>
            </person-group>
            <article-title>Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.</article-title>
            <source>Lancet</source>
            <year>2009</year>
            <month>Feb</month>
            <day>28</day>
            <volume>373</volume>
            <issue>9665</issue>
            <fpage>723</fpage>
            <page-range>723-31</page-range>
            <pub-id pub-id-type="pmid">19249633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Motovska</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Hlinomaz</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Miklik</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hromadka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Varvarovsky</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dusek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Knot</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jarkovsky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kala</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rokyta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tousek</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kramarikova</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Majtan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Simek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Branny</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mrozek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cervinka</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ostransky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Widimsky</surname>
                <given-names>P</given-names>
              </name>
              <collab>PRAGUE-18 Study Group</collab>
            </person-group>
            <article-title>Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study.</article-title>
            <source>Circulation</source>
            <year>2016</year>
            <month>Nov</month>
            <day>22</day>
            <volume>134</volume>
            <issue>21</issue>
            <fpage>1603</fpage>
            <page-range>1603-1612</page-range>
            <pub-id pub-id-type="pmid">27576777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiviott</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McCabe</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Montalescot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ruzyllo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Ardissino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De Servi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Riesmeyer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weerakkody</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Antman</surname>
                <given-names>EM</given-names>
              </name>
              <collab>TRITON-TIMI 38 Investigators</collab>
            </person-group>
            <article-title>Prasugrel versus clopidogrel in patients with acute coronary syndromes.</article-title>
            <source>N Engl J Med</source>
            <year>2007</year>
            <month>Nov</month>
            <day>15</day>
            <volume>357</volume>
            <issue>20</issue>
            <fpage>2001</fpage>
            <page-range>2001-15</page-range>
            <pub-id pub-id-type="pmid">17982182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roe</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Prabhakaran</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Cornel</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Clemmensen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ardissino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nicolau</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Boden</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Gurbel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Ruzyllo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dalby</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Leiva-Pons</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Parkhomenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Topacio</surname>
                <given-names>GO</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pavlides</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Goudev</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Oto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Merkely</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gasparovic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Corbalan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cintez&#x00103;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McLendon</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Winters</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Lokhnygina</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Aylward</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hochman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
              <collab>TRILOGY ACS Investigators</collab>
            </person-group>
            <article-title>Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>Oct</month>
            <day>04</day>
            <volume>367</volume>
            <issue>14</issue>
            <fpage>1297</fpage>
            <page-range>1297-309</page-range>
            <pub-id pub-id-type="pmid">22920930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Leonardi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gallup</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bramucci</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Radke</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Widimsk&#x000fd;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tousek</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tauth</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Spriggs</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McLaurin</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>G&#x000e9;n&#x000e9;reux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Prats</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Todd</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Skerjanec</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
              <collab>CHAMPION PHOENIX Investigators</collab>
            </person-group>
            <article-title>Effect of platelet inhibition with cangrelor during PCI on ischemic events.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Apr</month>
            <day>04</day>
            <volume>368</volume>
            <issue>14</issue>
            <fpage>1303</fpage>
            <page-range>1303-13</page-range>
            <pub-id pub-id-type="pmid">23473369</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Leonardi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Skerjanec</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Iwaoka</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Stuckey</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Gogia</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Gruberg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
              <collab>CHAMPION Investigators</collab>
            </person-group>
            <article-title>Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.</article-title>
            <source>Lancet</source>
            <year>2013</year>
            <month>Dec</month>
            <day>14</day>
            <volume>382</volume>
            <issue>9909</issue>
            <fpage>1981</fpage>
            <page-range>1981-92</page-range>
            <pub-id pub-id-type="pmid">24011551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Luca</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Suryapranata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Antoniucci</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tcheng</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Van de Werf</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Antman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Topol</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.</article-title>
            <source>JAMA</source>
            <year>2005</year>
            <month>Apr</month>
            <day>13</day>
            <volume>293</volume>
            <issue>14</issue>
            <fpage>1759</fpage>
            <page-range>1759-65</page-range>
            <pub-id pub-id-type="pmid">15827315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Witzenbichler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Guagliumi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Peruga</surname>
                <given-names>JZ</given-names>
              </name>
              <name>
                <surname>Brodie</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Dudek</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kornowski</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gersh</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Pocock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Dangas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Kirtane</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Parise</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mehran</surname>
                <given-names>R</given-names>
              </name>
              <collab>HORIZONS-AMI Trial Investigators</collab>
            </person-group>
            <article-title>Bivalirudin during primary PCI in acute myocardial infarction.</article-title>
            <source>N Engl J Med</source>
            <year>2008</year>
            <month>May</month>
            <day>22</day>
            <volume>358</volume>
            <issue>21</issue>
            <fpage>2218</fpage>
            <page-range>2218-30</page-range>
            <pub-id pub-id-type="pmid">18499566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>van 't Hof</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hamm</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Clemmensen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lapostolle</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Coste</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ten Berg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Van Grunsven</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Eggink</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Nibbe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zeymer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Campo dell' Orto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nef</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Steinmetz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Soulat</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Deliargyris</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schuette</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Prats</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Clayton</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pocock</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hamon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>P</given-names>
              </name>
              <collab>EUROMAX Investigators</collab>
            </person-group>
            <article-title>Bivalirudin started during emergency transport for primary PCI.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Dec</month>
            <day>05</day>
            <volume>369</volume>
            <issue>23</issue>
            <fpage>2207</fpage>
            <page-range>2207-17</page-range>
            <pub-id pub-id-type="pmid">24171490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Send&#x000f3;n</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Montalescot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Theroux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Claeys</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Cools</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Skene</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>McCabe</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
              <collab>CLARITY-TIMI 28 Investigators</collab>
            </person-group>
            <article-title>Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <month>Mar</month>
            <day>24</day>
            <volume>352</volume>
            <issue>12</issue>
            <fpage>1179</fpage>
            <page-range>1179-89</page-range>
            <pub-id pub-id-type="pmid">15758000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>LX</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>JX</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>LS</given-names>
              </name>
              <collab>COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group</collab>
            </person-group>
            <article-title>Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.</article-title>
            <source>Lancet</source>
            <year>2005</year>
            <month>Nov</month>
            <day>05</day>
            <volume>366</volume>
            <issue>9497</issue>
            <fpage>1607</fpage>
            <page-range>1607-21</page-range>
            <pub-id pub-id-type="pmid">16271642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berwanger</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Nicolau</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Nicholls</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Parkhomenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Averkov</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Tajer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Malaga</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Saraiva</surname>
                <given-names>JFK</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>De Luca</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Guimaraes</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>de Barros E Silva</surname>
                <given-names>PGM</given-names>
              </name>
              <name>
                <surname>Damiani</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Paisani</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Lasagno</surname>
                <given-names>CMR</given-names>
              </name>
              <name>
                <surname>Candido</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Valeis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Moia</surname>
                <given-names>DDF</given-names>
              </name>
              <name>
                <surname>Piegas</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>RD</given-names>
              </name>
              <collab>TREAT Study Group</collab>
            </person-group>
            <article-title>Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial.</article-title>
            <source>JAMA Cardiol</source>
            <year>2018</year>
            <month>May</month>
            <day>01</day>
            <volume>3</volume>
            <issue>5</issue>
            <fpage>391</fpage>
            <page-range>391-399</page-range>
            <pub-id pub-id-type="pmid">29525822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montalescot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zeymer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Silvain</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boulanger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ecollan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Combes</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pollack</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>B&#x000e9;nezet</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Stibbe</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Filippi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Teiger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cayla</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Elhadad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Adnet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chouihed</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gallula</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Greffet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aout</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Collet</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Vicaut</surname>
                <given-names>E</given-names>
              </name>
              <collab>ATOLL Investigators</collab>
            </person-group>
            <article-title>Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.</article-title>
            <source>Lancet</source>
            <year>2011</year>
            <month>Aug</month>
            <day>20</day>
            <volume>378</volume>
            <issue>9792</issue>
            <fpage>693</fpage>
            <page-range>693-703</page-range>
            <pub-id pub-id-type="pmid">21856483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hai-Long</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xiao-Hua</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jian-Jun</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The Efficacy and Safety of Enoxaparin: A Meta-analysis.</article-title>
            <source>Open Med (Wars)</source>
            <year>2018</year>
            <volume>13</volume>
            <fpage>359</fpage>
            <page-range>359-365</page-range>
            <pub-id pub-id-type="pmid">30211318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silvain</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Beygui</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barth&#x000e9;l&#x000e9;my</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Pollack</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zeymer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cayla</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Collet</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Vicaut</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Montalescot</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis.</article-title>
            <source>BMJ</source>
            <year>2012</year>
            <month>Feb</month>
            <day>03</day>
            <volume>344</volume>
            <fpage>e553</fpage>
            <pub-id pub-id-type="pmid">22306479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valgimigli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frigoli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leonardi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rothenb&#x000fc;hler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gagnor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Calabr&#x000f2;</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Garducci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rubartelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Briguori</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>And&#x000f2;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Repetto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Limbruno</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Garbo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sganzerla</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lupi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cortese</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ausiello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ierna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Presbitero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Santarelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sardella</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Varbella</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tresoldi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Cesare</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rigattieri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zingarelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tosi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van 't Hof</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boccuzzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Omerovic</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sabat&#x000e9;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>J&#x000fc;ni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vranckx</surname>
                <given-names>P</given-names>
              </name>
              <collab>MATRIX Investigators</collab>
            </person-group>
            <article-title>Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Sep</month>
            <day>10</day>
            <volume>373</volume>
            <issue>11</issue>
            <fpage>997</fpage>
            <page-range>997-1009</page-range>
            <pub-id pub-id-type="pmid">26324049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grimfj&#x000e4;rd</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Erlinge</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Koul</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lagerqvist</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Svennblad</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Varenhorst</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Unfractionated heparin versus bivalirudin in patients undergoing primary percutaneous coronary intervention: a SWEDEHEART study.</article-title>
            <source>EuroIntervention</source>
            <year>2017</year>
            <month>Mar</month>
            <day>20</day>
            <volume>12</volume>
            <issue>16</issue>
            <fpage>2009</fpage>
            <page-range>2009-2017</page-range>
            <pub-id pub-id-type="pmid">28044990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <collab>Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators</collab>
            <article-title>Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.</article-title>
            <source>Lancet</source>
            <year>2001</year>
            <month>Aug</month>
            <day>25</day>
            <volume>358</volume>
            <issue>9282</issue>
            <fpage>605</fpage>
            <page-range>605-13</page-range>
            <pub-id pub-id-type="pmid">11530146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>McCabe</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
              <collab>ExTRACT-TIMI 25 Investigators</collab>
            </person-group>
            <article-title>Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25).</article-title>
            <source>Am Heart J</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>149</volume>
            <issue>2</issue>
            <fpage>217</fpage>
            <page-range>217-26</page-range>
            <pub-id pub-id-type="pmid">15846258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>LX</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>JX</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>LS</given-names>
              </name>
              <collab>COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group</collab>
            </person-group>
            <article-title>Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.</article-title>
            <source>Lancet</source>
            <year>2005</year>
            <month>Nov</month>
            <day>05</day>
            <volume>366</volume>
            <issue>9497</issue>
            <fpage>1622</fpage>
            <page-range>1622-32</page-range>
            <pub-id pub-id-type="pmid">16271643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pfisterer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Brener</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Naylor</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Califf</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>van de Werf</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stebbins</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Topol</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>PW</given-names>
              </name>
            </person-group>
            <article-title>Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>634</fpage>
            <page-range>634-40</page-range>
            <pub-id pub-id-type="pmid">9741504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chatterjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chaudhuri</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vedanthan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fuster</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ibanez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bangalore</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Early intravenous beta-blockers in patients with acute coronary syndrome--a meta-analysis of randomized trials.</article-title>
            <source>Int J Cardiol</source>
            <year>2013</year>
            <month>Sep</month>
            <day>30</day>
            <volume>168</volume>
            <issue>2</issue>
            <fpage>915</fpage>
            <page-range>915-21</page-range>
            <pub-id pub-id-type="pmid">23168009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dargie</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.</article-title>
            <source>Lancet</source>
            <year>2001</year>
            <month>May</month>
            <day>05</day>
            <volume>357</volume>
            <issue>9266</issue>
            <fpage>1385</fpage>
            <page-range>1385-90</page-range>
            <pub-id pub-id-type="pmid">11356434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <article-title>ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.</article-title>
            <source>Lancet</source>
            <year>1995</year>
            <month>Mar</month>
            <day>18</day>
            <volume>345</volume>
            <issue>8951</issue>
            <fpage>669</fpage>
            <page-range>669-85</page-range>
            <pub-id pub-id-type="pmid">7661937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hofmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Jernberg</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lindahl</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Erlinge</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Witt</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Arefalk</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Frick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alfredsson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ravn-Fischer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Omerovic</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kellerth</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sparv</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ekelund</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Linder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ekstr&#x000f6;m</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lauermann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Haaga</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Pernow</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>&#x000d6;stlund</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Herlitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Svensson</surname>
                <given-names>L</given-names>
              </name>
              <collab>DETO2X&#x02013;SWEDEHEART Investigators</collab>
            </person-group>
            <article-title>Oxygen Therapy in Suspected Acute Myocardial Infarction.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Sep</month>
            <day>28</day>
            <volume>377</volume>
            <issue>13</issue>
            <fpage>1240</fpage>
            <page-range>1240-1249</page-range>
            <pub-id pub-id-type="pmid">28844200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Remme</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Neaton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Roniker</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bittman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hurley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kleiman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gatlin</surname>
                <given-names>M</given-names>
              </name>
              <collab>Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators</collab>
            </person-group>
            <article-title>Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.</article-title>
            <source>N Engl J Med</source>
            <year>2003</year>
            <month>Apr</month>
            <day>03</day>
            <volume>348</volume>
            <issue>14</issue>
            <fpage>1309</fpage>
            <page-range>1309-21</page-range>
            <pub-id pub-id-type="pmid">12668699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Remme</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Cody</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Castaigne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palensky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wittes</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.</article-title>
            <source>N Engl J Med</source>
            <year>1999</year>
            <month>Sep</month>
            <day>02</day>
            <volume>341</volume>
            <issue>10</issue>
            <fpage>709</fpage>
            <page-range>709-17</page-range>
            <pub-id pub-id-type="pmid">10471456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Krum</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>van Veldhuisen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Swedberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pocock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <collab>EMPHASIS-HF Study Group</collab>
            </person-group>
            <article-title>Eplerenone in patients with systolic heart failure and mild symptoms.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Jan</month>
            <day>06</day>
            <volume>364</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-21</page-range>
            <pub-id pub-id-type="pmid">21073363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Girerd</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Collier</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pocock</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Krum</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Swedberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Van Veldhuisen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.</article-title>
            <source>Eur Heart J</source>
            <year>2015</year>
            <month>Sep</month>
            <day>07</day>
            <volume>36</volume>
            <issue>34</issue>
            <fpage>2310</fpage>
            <page-range>2310-7</page-range>
            <pub-id pub-id-type="pmid">26093641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berwanger</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Santucci</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>de Barros E Silva</surname>
                <given-names>PGM</given-names>
              </name>
              <name>
                <surname>Jesu&#x000ed;no</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Damiani</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Barbosa</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>RHN</given-names>
              </name>
              <name>
                <surname>Laranjeira</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Egydio</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Borges de Oliveira</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dall Orto</surname>
                <given-names>FTC</given-names>
              </name>
              <name>
                <surname>Beraldo de Andrade</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bienert</surname>
                <given-names>IRC</given-names>
              </name>
              <name>
                <surname>Bosso</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Mangione</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Polanczyk</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Sousa</surname>
                <given-names>AGMR</given-names>
              </name>
              <name>
                <surname>Kalil</surname>
                <given-names>RAK</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Sposito</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Rech</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Sousa</surname>
                <given-names>ACS</given-names>
              </name>
              <name>
                <surname>Baldissera</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nascimento</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Giraldez</surname>
                <given-names>RRCV</given-names>
              </name>
              <name>
                <surname>Cavalcanti</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Mattos</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Armaganijan</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Guimar&#x000e3;es</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Sousa</surname>
                <given-names>JEMR</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>RD</given-names>
              </name>
              <collab>SECURE-PCI Investigators</collab>
            </person-group>
            <article-title>Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2018</year>
            <month>Apr</month>
            <day>03</day>
            <volume>319</volume>
            <issue>13</issue>
            <fpage>1331</fpage>
            <page-range>1331-1340</page-range>
            <pub-id pub-id-type="pmid">29525821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szarek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Alings</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Bittner</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Edelberg</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Hanotin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Jukema</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kiss</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Lecorps</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Moryusef</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pordy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Roe</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Tricoci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Xavier</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zeiher</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <collab>ODYSSEY OUTCOMES Committees and Investigators</collab>
            </person-group>
            <article-title>Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2019</year>
            <month>Feb</month>
            <day>05</day>
            <volume>73</volume>
            <issue>4</issue>
            <fpage>387</fpage>
            <page-range>387-396</page-range>
            <pub-id pub-id-type="pmid">30428396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Giugliano</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Keech</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Honarpour</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wiviott</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kuder</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wasserman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Sever</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>TR</given-names>
              </name>
              <collab>FOURIER Steering Committee and Investigators</collab>
            </person-group>
            <article-title>Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>May</month>
            <day>04</day>
            <volume>376</volume>
            <issue>18</issue>
            <fpage>1713</fpage>
            <page-range>1713-1722</page-range>
            <pub-id pub-id-type="pmid">28304224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amsterdam</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Wenger</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Brindis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Ganiats</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Jneid</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Kontos</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Liebson</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Smalling</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Zieman</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2014</year>
            <month>Dec</month>
            <day>23</day>
            <volume>64</volume>
            <issue>24</issue>
            <fpage>e139</fpage>
            <page-range>e139-e228</page-range>
            <pub-id pub-id-type="pmid">25260718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bavry</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Kumbhani</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Rassi</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Askari</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2006</year>
            <month>Oct</month>
            <day>03</day>
            <volume>48</volume>
            <issue>7</issue>
            <fpage>1319</fpage>
            <page-range>1319-25</page-range>
            <pub-id pub-id-type="pmid">17010789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fox</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Clayton</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Damman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pocock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>de Winter</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Tijssen</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Lagerqvist</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wallentin</surname>
                <given-names>L</given-names>
              </name>
              <collab>FIR Collaboration</collab>
            </person-group>
            <article-title>Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2010</year>
            <month>Jun</month>
            <day>01</day>
            <volume>55</volume>
            <issue>22</issue>
            <fpage>2435</fpage>
            <page-range>2435-45</page-range>
            <pub-id pub-id-type="pmid">20359842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savonitto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cavallini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Petronio</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Murena</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Antonicelli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sacco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Steffenino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bonechi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mossuti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Manari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tolaro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Toso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Daniotti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Piscione</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Morici</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cesana</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Jori</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>De Servi</surname>
                <given-names>S</given-names>
              </name>
              <collab>Italian Elderly ACS Trial Investigators</collab>
            </person-group>
            <article-title>Early aggressive versus initially conservative treatment in elderly patients with non-ST-segment elevation acute coronary syndrome: a randomized controlled trial.</article-title>
            <source>JACC Cardiovasc Interv</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>5</volume>
            <issue>9</issue>
            <fpage>906</fpage>
            <page-range>906-16</page-range>
            <pub-id pub-id-type="pmid">22995877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Charytan</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Wallentin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lagerqvist</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Spacek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>De Winter</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Choudhry</surname>
                <given-names>NK</given-names>
              </name>
            </person-group>
            <article-title>Early angiography in patients with chronic kidney disease: a collaborative systematic review.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>1032</fpage>
            <page-range>1032-43</page-range>
            <pub-id pub-id-type="pmid">19423566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alfredsson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lindb&#x000e4;ck</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wallentin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Swahn</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Similar outcome with an invasive strategy in men and women with non-ST-elevation acute coronary syndromes: from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART).</article-title>
            <source>Eur Heart J</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>32</volume>
            <issue>24</issue>
            <fpage>3128</fpage>
            <page-range>3128-36</page-range>
            <pub-id pub-id-type="pmid">21911338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Antithrombotic Trialists' (ATT) Collaboration</collab>
              <name>
                <surname>Baigent</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Blackwell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Emberson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Godwin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Buring</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hennekens</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kearney</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Meade</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Patrono</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Roncaglioni</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Zanchetti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.</article-title>
            <source>Lancet</source>
            <year>2009</year>
            <month>May</month>
            <day>30</day>
            <volume>373</volume>
            <issue>9678</issue>
            <fpage>1849</fpage>
            <page-range>1849-60</page-range>
            <pub-id pub-id-type="pmid">19482214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <article-title>Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group.</article-title>
            <source>Lancet</source>
            <year>1990</year>
            <month>Oct</month>
            <day>06</day>
            <volume>336</volume>
            <issue>8719</issue>
            <fpage>827</fpage>
            <page-range>827-30</page-range>
            <pub-id pub-id-type="pmid">1976875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Archibald</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Steinke</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Smitherman</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Doherty</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Schnaper</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>LeWinter</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Linares</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pouget</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sabharwal</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Chesler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>DeMots</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.</article-title>
            <source>N Engl J Med</source>
            <year>1983</year>
            <month>Aug</month>
            <day>18</day>
            <volume>309</volume>
            <issue>7</issue>
            <fpage>396</fpage>
            <page-range>396-403</page-range>
            <pub-id pub-id-type="pmid">6135989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fanaroff</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Kaltenbach</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Akhter</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Effron</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>TY</given-names>
              </name>
            </person-group>
            <article-title>Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2018</year>
            <month>Feb</month>
            <day>08</day>
            <volume>7</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">29437596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Chrolavicius</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tognoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>KK</given-names>
              </name>
              <collab>Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators</collab>
            </person-group>
            <article-title>Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.</article-title>
            <source>N Engl J Med</source>
            <year>2001</year>
            <month>Aug</month>
            <day>16</day>
            <volume>345</volume>
            <issue>7</issue>
            <fpage>494</fpage>
            <page-range>494-502</page-range>
            <pub-id pub-id-type="pmid">11519503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehta</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Bertrand</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Natarajan</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Malmberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rupprecht</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chrolavicius</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Copland</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>KA</given-names>
              </name>
              <collab>Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators</collab>
            </person-group>
            <article-title>Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.</article-title>
            <source>Lancet</source>
            <year>2001</year>
            <month>Aug</month>
            <day>18</day>
            <volume>358</volume>
            <issue>9281</issue>
            <fpage>527</fpage>
            <page-range>527-33</page-range>
            <pub-id pub-id-type="pmid">11520521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kristensen</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Knuuti</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saraste</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>B&#x000f8;tker</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Hert</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gonzalez-Juanatey</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Gorenek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Heyndrickx</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Hoeft</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iung</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Longrois</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>L&#x000fc;scher</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Pierard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pocock</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roffi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sirnes</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Sousa-Uva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Voudris</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Funck-Brentano</surname>
                <given-names>C</given-names>
              </name>
              <collab>Authors/Task Force Members</collab>
            </person-group>
            <article-title>2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA).</article-title>
            <source>Eur Heart J</source>
            <year>2014</year>
            <month>Sep</month>
            <day>14</day>
            <volume>35</volume>
            <issue>35</issue>
            <fpage>2383</fpage>
            <page-range>2383-431</page-range>
            <pub-id pub-id-type="pmid">25086026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Bertrand</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Moses</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Lincoff</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ware</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Pocock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>McLaurin</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Jafar</surname>
                <given-names>MZ</given-names>
              </name>
              <name>
                <surname>Chandna</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Leisch</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Strasser</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Desaga</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stuckey</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Zelman</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Lieber</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Mehran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <collab>ACUITY Investigators</collab>
            </person-group>
            <article-title>Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.</article-title>
            <source>JAMA</source>
            <year>2007</year>
            <month>Feb</month>
            <day>14</day>
            <volume>297</volume>
            <issue>6</issue>
            <fpage>591</fpage>
            <page-range>591-602</page-range>
            <pub-id pub-id-type="pmid">17299194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giugliano</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bode</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Montalescot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>van 't Hof</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berdan</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Strony</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Hildemann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Veltri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Van de Werf</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Califf</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <collab>EARLY ACS Investigators</collab>
            </person-group>
            <article-title>Early versus delayed, provisional eptifibatide in acute coronary syndromes.</article-title>
            <source>N Engl J Med</source>
            <year>2009</year>
            <month>May</month>
            <day>21</day>
            <volume>360</volume>
            <issue>21</issue>
            <fpage>2176</fpage>
            <page-range>2176-90</page-range>
            <pub-id pub-id-type="pmid">19332455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kastrati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mehilli</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Dotzer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>ten Berg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bollwein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Graf</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pache</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Seyfarth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sch&#x000fc;hlen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dirschinger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;mig</surname>
                <given-names>A</given-names>
              </name>
              <collab>Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators</collab>
            </person-group>
            <article-title>Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.</article-title>
            <source>JAMA</source>
            <year>2006</year>
            <month>Apr</month>
            <day>05</day>
            <volume>295</volume>
            <issue>13</issue>
            <fpage>1531</fpage>
            <page-range>1531-8</page-range>
            <pub-id pub-id-type="pmid">16533938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eikelboom</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Anand</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Malmberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Weitz</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Ginsberg</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.</article-title>
            <source>Lancet</source>
            <year>2000</year>
            <month>Jun</month>
            <day>03</day>
            <volume>355</volume>
            <issue>9219</issue>
            <fpage>1936</fpage>
            <page-range>1936-42</page-range>
            <pub-id pub-id-type="pmid">10859038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferguson</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Califf</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Antman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grines</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kereiakes</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Langer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Nessel</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Avezum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aylward</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Biasucci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Borzak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Col</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frey</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Fry</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gulba</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Guneri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gurfinkel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hochman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kleiman</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Leon</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Lopez-Sendon</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Pepine</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Ruzyllo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Steinhubl</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Teirstein</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Toro-Figueroa</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>H</given-names>
              </name>
              <collab>SYNERGY Trial Investigators</collab>
            </person-group>
            <article-title>Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.</article-title>
            <source>JAMA</source>
            <year>2004</year>
            <month>Jul</month>
            <day>07</day>
            <volume>292</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-54</page-range>
            <pub-id pub-id-type="pmid">15238590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Antman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kleiman</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Berdan</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Reist</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Langer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Aylward</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Col</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Califf</surname>
                <given-names>RM</given-names>
              </name>
              <collab>SYNERGY Trial Investigators</collab>
            </person-group>
            <article-title>High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial.</article-title>
            <source>JAMA</source>
            <year>2005</year>
            <month>Nov</month>
            <day>23</day>
            <volume>294</volume>
            <issue>20</issue>
            <fpage>2594</fpage>
            <page-range>2594-600</page-range>
            <pub-id pub-id-type="pmid">16304073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators</collab>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Chrolavicius</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Afzal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pogue</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Budaj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Bassand</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Wallentin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Joyner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Comparison of fondaparinux and enoxaparin in acute coronary syndromes.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>Apr</month>
            <day>06</day>
            <volume>354</volume>
            <issue>14</issue>
            <fpage>1464</fpage>
            <page-range>1464-76</page-range>
            <pub-id pub-id-type="pmid">16537663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jolly</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Xavier</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rupprecht</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Lopez-Sendon</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chrolavicius</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Pogue</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Laing</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux.</article-title>
            <source>Am Heart J</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>160</volume>
            <issue>6</issue>
            <fpage>1029</fpage>
            <page-range>1029-34, 1034.e1</page-range>
            <pub-id pub-id-type="pmid">21146654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Demers</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>ESSENCE trial results: breaking new ground. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events.</article-title>
            <source>Can J Cardiol</source>
            <year>1998</year>
            <month>Aug</month>
            <volume>14 Suppl E</volume>
            <fpage>15E</fpage>
            <page-range>15E-19E</page-range>
            <pub-id pub-id-type="pmid">9779028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>McCabe</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Gurfinkel</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Turpie</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Bernink</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Salein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bayes De Luna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lablanche</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Radley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Premmereur</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.</article-title>
            <source>Circulation</source>
            <year>1999</year>
            <month>Oct</month>
            <day>12</day>
            <volume>100</volume>
            <issue>15</issue>
            <fpage>1593</fpage>
            <page-range>1593-601</page-range>
            <pub-id pub-id-type="pmid">10517729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McCabe</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Rader</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Rouleau</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Belder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Joyal</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Skene</surname>
                <given-names>AM</given-names>
              </name>
              <collab>Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators</collab>
            </person-group>
            <article-title>Intensive versus moderate lipid lowering with statins after acute coronary syndromes.</article-title>
            <source>N Engl J Med</source>
            <year>2004</year>
            <month>Apr</month>
            <day>08</day>
            <volume>350</volume>
            <issue>15</issue>
            <fpage>1495</fpage>
            <page-range>1495-504</page-range>
            <pub-id pub-id-type="pmid">15007110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Cholesterol Treatment Trialists&#x02019; (CTT) Collaboration</collab>
              <name>
                <surname>Baigent</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Blackwell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Emberson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Reith</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bhala</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Keech</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.</article-title>
            <source>Lancet</source>
            <year>2010</year>
            <month>Nov</month>
            <day>13</day>
            <volume>376</volume>
            <issue>9753</issue>
            <fpage>1670</fpage>
            <page-range>1670-81</page-range>
            <pub-id pub-id-type="pmid">21067804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LaRosa</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Grundy</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Shear</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barter</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fruchart</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Gotto</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Greten</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kastelein</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Shepherd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wenger</surname>
                <given-names>NK</given-names>
              </name>
              <collab>Treating to New Targets (TNT) Investigators</collab>
            </person-group>
            <article-title>Intensive lipid lowering with atorvastatin in patients with stable coronary disease.</article-title>
            <source>N Engl J Med</source>
            <year>2005</year>
            <month>Apr</month>
            <day>07</day>
            <volume>352</volume>
            <issue>14</issue>
            <fpage>1425</fpage>
            <page-range>1425-35</page-range>
            <pub-id pub-id-type="pmid">15755765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moy&#x000e9;</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Basta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Cuddy</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Geltman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Flaker</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.</article-title>
            <source>N Engl J Med</source>
            <year>1992</year>
            <month>Sep</month>
            <day>03</day>
            <volume>327</volume>
            <issue>10</issue>
            <fpage>669</fpage>
            <page-range>669-77</page-range>
            <pub-id pub-id-type="pmid">1386652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Velazquez</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Rouleau</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>K&#x000f8;ber</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Maggioni</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Swedberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Van de Werf</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Leimberger</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Henis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zelenkofske</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sellers</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Califf</surname>
                <given-names>RM</given-names>
              </name>
              <collab>Valsartan in Acute Myocardial Infarction Trial Investigators</collab>
            </person-group>
            <article-title>Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.</article-title>
            <source>N Engl J Med</source>
            <year>2003</year>
            <month>Nov</month>
            <day>13</day>
            <volume>349</volume>
            <issue>20</issue>
            <fpage>1893</fpage>
            <page-range>1893-906</page-range>
            <pub-id pub-id-type="pmid">14610160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>McMurray</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Held</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Michelson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Olofsson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ostergren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Swedberg</surname>
                <given-names>K</given-names>
              </name>
              <collab>CHARM Investigators and Committees</collab>
            </person-group>
            <article-title>Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.</article-title>
            <source>Lancet</source>
            <year>2003</year>
            <month>Sep</month>
            <day>06</day>
            <volume>362</volume>
            <issue>9386</issue>
            <fpage>772</fpage>
            <page-range>772-6</page-range>
            <pub-id pub-id-type="pmid">13678870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>ONTARGET Investigators</collab>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Teo</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Pogue</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dyal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Copland</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Schumacher</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dagenais</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sleight</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Telmisartan, ramipril, or both in patients at high risk for vascular events.</article-title>
            <source>N Engl J Med</source>
            <year>2008</year>
            <month>Apr</month>
            <day>10</day>
            <volume>358</volume>
            <issue>15</issue>
            <fpage>1547</fpage>
            <page-range>1547-59</page-range>
            <pub-id pub-id-type="pmid">18378520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Heart Outcomes Prevention Evaluation Study Investigators</collab>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sleight</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pogue</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dagenais</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.</article-title>
            <source>N Engl J Med</source>
            <year>2000</year>
            <month>Jan</month>
            <day>20</day>
            <volume>342</volume>
            <issue>3</issue>
            <fpage>145</fpage>
            <page-range>145-53</page-range>
            <pub-id pub-id-type="pmid">10639539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <article-title>The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.</article-title>
            <source>Lancet</source>
            <year>1999</year>
            <month>Jan</month>
            <day>02</day>
            <volume>353</volume>
            <issue>9146</issue>
            <fpage>9</fpage>
            <page-range>9-13</page-range>
            <pub-id pub-id-type="pmid">10023943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Packer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coats</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Katus</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Krum</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mohacsi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rouleau</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Tendera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Castaigne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roecker</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Schultz</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>DeMets</surname>
                <given-names>DL</given-names>
              </name>
              <collab>Carvedilol Prospective Randomized Cumulative Survival Study Group</collab>
            </person-group>
            <article-title>Effect of carvedilol on survival in severe chronic heart failure.</article-title>
            <source>N Engl J Med</source>
            <year>2001</year>
            <month>May</month>
            <day>31</day>
            <volume>344</volume>
            <issue>22</issue>
            <fpage>1651</fpage>
            <page-range>1651-8</page-range>
            <pub-id pub-id-type="pmid">11386263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <article-title>Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).</article-title>
            <source>Lancet</source>
            <year>1999</year>
            <month>Jun</month>
            <day>12</day>
            <volume>353</volume>
            <issue>9169</issue>
            <fpage>2001</fpage>
            <page-range>2001-7</page-range>
            <pub-id pub-id-type="pmid">10376614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flather</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Shibata</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Coats</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Van Veldhuisen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Parkhomenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Borbola</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cohen-Solal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dumitrascu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lechat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Soler-Soler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tavazzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Spinarova</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Toman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anker</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Poole-Wilson</surname>
                <given-names>PA</given-names>
              </name>
              <collab>SENIORS Investigators</collab>
            </person-group>
            <article-title>Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).</article-title>
            <source>Eur Heart J</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>215</fpage>
            <page-range>215-25</page-range>
            <pub-id pub-id-type="pmid">15642700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levine</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Bittl</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Brindis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Fihn</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Fleisher</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Mauri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mehran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Al-Khatib</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Birtcher</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brindis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Cigarroa</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Fleisher</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Gentile</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hlatky</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ikonomidis</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Joglar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Pressler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Wijeysundera</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>152</volume>
            <issue>5</issue>
            <fpage>1243</fpage>
            <page-range>1243-1275</page-range>
            <pub-id pub-id-type="pmid">27751237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Clare</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Lodge</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Jolicoeur</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Mark</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Clopidogrel use and bleeding after coronary artery bypass graft surgery.</article-title>
            <source>Am Heart J</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>156</volume>
            <issue>5</issue>
            <fpage>886</fpage>
            <page-range>886-92</page-range>
            <pub-id pub-id-type="pmid">19061702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fox</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lakkis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gersh</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
              <collab>Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial</collab>
            </person-group>
            <article-title>Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.</article-title>
            <source>Circulation</source>
            <year>2004</year>
            <month>Sep</month>
            <day>07</day>
            <volume>110</volume>
            <issue>10</issue>
            <fpage>1202</fpage>
            <page-range>1202-8</page-range>
            <pub-id pub-id-type="pmid">15313956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r93">
          <label>93</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dewilde</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Oirbans</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Verheugt</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Kelder</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>De Smet</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Herrman</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Adriaenssens</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vrolix</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heestermans</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Vis</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Tijsen</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>van 't Hof</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>ten Berg</surname>
                <given-names>JM</given-names>
              </name>
              <collab>WOEST study investigators</collab>
            </person-group>
            <article-title>Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.</article-title>
            <source>Lancet</source>
            <year>2013</year>
            <month>Mar</month>
            <day>30</day>
            <volume>381</volume>
            <issue>9872</issue>
            <fpage>1107</fpage>
            <page-range>1107-15</page-range>
            <pub-id pub-id-type="pmid">23415013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fiedler</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Maeng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mehilli</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schulz-Sch&#x000fc;pke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Byrne</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Sibbing</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoppmann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fusaro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ott</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kristensen</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Massberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schunkert</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Laugwitz</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Kastrati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sarafoff</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2015</year>
            <month>Apr</month>
            <day>28</day>
            <volume>65</volume>
            <issue>16</issue>
            <fpage>1619</fpage>
            <page-range>1619-1629</page-range>
            <pub-id pub-id-type="pmid">25908066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r95">
          <label>95</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Mehran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bode</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Verheugt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wildgoose</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>van Eickels</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lip</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Husted</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).</article-title>
            <source>Am Heart J</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>169</volume>
            <issue>4</issue>
            <fpage>472</fpage>
            <page-range>472-8.e5</page-range>
            <pub-id pub-id-type="pmid">25819853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Oldgren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lip</surname>
                <given-names>GYH</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Maeng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Merkely</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zeymer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Gropper</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nordaby</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kleine</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Manassie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Januzzi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ten Berg</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Hohnloser</surname>
                <given-names>SH</given-names>
              </name>
              <collab>RE-DUAL PCI Steering Committee and Investigators</collab>
            </person-group>
            <article-title>Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Oct</month>
            <day>19</day>
            <volume>377</volume>
            <issue>16</issue>
            <fpage>1513</fpage>
            <page-range>1513-1524</page-range>
            <pub-id pub-id-type="pmid">28844193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lopes</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Heizer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aronson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vora</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Massaro</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mehran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Windecker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Darius</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Averkov</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bahit</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Berwanger</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Budaj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hijazi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Parkhomenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sinnaeve</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Storey</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vinereanu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>JH</given-names>
              </name>
              <collab>AUGUSTUS Investigators</collab>
            </person-group>
            <article-title>Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Apr</month>
            <day>18</day>
            <volume>380</volume>
            <issue>16</issue>
            <fpage>1509</fpage>
            <page-range>1509-1524</page-range>
            <pub-id pub-id-type="pmid">30883055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thiele</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Desch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eitel</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>de Waha</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Management of cardiogenic shock.</article-title>
            <source>Eur Heart J</source>
            <year>2015</year>
            <month>May</month>
            <day>21</day>
            <volume>36</volume>
            <issue>20</issue>
            <fpage>1223</fpage>
            <page-range>1223-30</page-range>
            <pub-id pub-id-type="pmid">25732762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stegman</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Hochman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Post-myocardial infarction cardiogenic shock is a systemic illness in need of systemic treatment: is therapeutic hypothermia one possibility?</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2012</year>
            <month>Feb</month>
            <day>14</day>
            <volume>59</volume>
            <issue>7</issue>
            <fpage>644</fpage>
            <page-range>644-7</page-range>
            <pub-id pub-id-type="pmid">22322079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rihal</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Naidu</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Givertz</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Szeto</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kapur</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Kern</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garratt</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dimas</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>T</given-names>
              </name>
              <collab>Society for Cardiovascular Angiography and Interventions (SCAI)</collab>
              <collab>Heart Failure Society of America (HFSA)</collab>
              <collab>Society for Thoracic Surgeons (STS)</collab>
              <collab>American Heart Association (AHA)</collab>
              <collab>American College of Cardiology (ACC)</collab>
            </person-group>
            <article-title>2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care (Endorsed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'intervention).</article-title>
            <source>J Card Fail</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>499</fpage>
            <page-range>499-518</page-range>
            <pub-id pub-id-type="pmid">26036425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bagai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brilakis</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Update in the Management of Acute Coronary Syndrome Patients with Cardiogenic Shock.</article-title>
            <source>Curr Cardiol Rep</source>
            <year>2019</year>
            <month>Mar</month>
            <day>04</day>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>17</fpage>
            <pub-id pub-id-type="pmid">30828750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r102">
          <label>102</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thiele</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Akin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sandri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fuernau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>de Waha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Meyer-Saraei</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nordbeck</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Geisler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Landmesser</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Skurk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fach</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lapp</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Piek</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Noc</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goslar</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Felix</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Stepinska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oldroyd</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Serpytis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Montalescot</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barthelemy</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Windecker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Savonitto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Torremante</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vrints</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Desch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zeymer</surname>
                <given-names>U</given-names>
              </name>
              <collab>CULPRIT-SHOCK Investigators</collab>
            </person-group>
            <article-title>PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Dec</month>
            <day>21</day>
            <volume>377</volume>
            <issue>25</issue>
            <fpage>2419</fpage>
            <page-range>2419-2432</page-range>
            <pub-id pub-id-type="pmid">29083953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Ascheim</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>de Lemos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ettinger</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fesmire</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Linderbaum</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Ornato</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Tamis-Holland</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tommaso</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>DX</given-names>
              </name>
              <collab>American College of Cardiology Foundation</collab>
              <collab>American Heart Association Task Force on Practice Guidelines</collab>
              <collab>American College of Emergency Physicians</collab>
              <collab>Society for Cardiovascular Angiography and Interventions</collab>
            </person-group>
            <article-title>2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions.</article-title>
            <source>Catheter Cardiovasc Interv</source>
            <year>2013</year>
            <month>Jul</month>
            <day>01</day>
            <volume>82</volume>
            <issue>1</issue>
            <fpage>E1</fpage>
            <page-range>E1-27</page-range>
            <pub-id pub-id-type="pmid">23299937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gale</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Cattle</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Woolston</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baxter</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Simms</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Blaxill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Greenwood</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>West</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Resolving inequalities in care? Reduced mortality in the elderly after acute coronary syndromes. The Myocardial Ischaemia National Audit Project 2003-2010.</article-title>
            <source>Eur Heart J</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>630</fpage>
            <page-range>630-9</page-range>
            <pub-id pub-id-type="pmid">22009446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Canto</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Wenger</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Vaccarino</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kiefe</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Frederick</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Sopko</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>ZJ</given-names>
              </name>
              <collab>NRMI Investigators</collab>
            </person-group>
            <article-title>Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality.</article-title>
            <source>JAMA</source>
            <year>2012</year>
            <month>Feb</month>
            <day>22</day>
            <volume>307</volume>
            <issue>8</issue>
            <fpage>813</fpage>
            <page-range>813-22</page-range>
            <pub-id pub-id-type="pmid">22357832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Gore</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Eagle</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Gurfinkel</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Quill</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>FA</given-names>
              </name>
            </person-group>
            <article-title>Age and sex differences, and changing trends, in the use of evidence-based therapies in acute coronary syndromes: perspectives from a multinational registry.</article-title>
            <source>Coron Artery Dis</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>336</fpage>
            <page-range>336-44</page-range>
            <pub-id pub-id-type="pmid">20661139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r107">
          <label>107</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eisen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giugliano</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Antiplatelet and Anticoagulation Treatment in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: Comparison of the Updated North American and European Guidelines.</article-title>
            <source>Cardiol Rev</source>
            <year>2016</year>
            <season>Jul-Aug</season>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>170</fpage>
            <page-range>170-6</page-range>
            <pub-id pub-id-type="pmid">26186386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r108">
          <label>108</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Bugiardini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bierman</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Eagle</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Huynh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Grondin</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Schenck-Gustafsson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Bridging the gender gap: Insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients with acute coronary syndromes.</article-title>
            <source>Am Heart J</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>163</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <page-range>66-73</page-range>
            <pub-id pub-id-type="pmid">22172438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r109">
          <label>109</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehta</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Beckie</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>DeVon</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Grines</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Lindley</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Vaccarino</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Wenger</surname>
                <given-names>NK</given-names>
              </name>
              <collab>American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Cardiovascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research</collab>
            </person-group>
            <article-title>Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2016</year>
            <month>Mar</month>
            <day>01</day>
            <volume>133</volume>
            <issue>9</issue>
            <fpage>916</fpage>
            <page-range>916-47</page-range>
            <pub-id pub-id-type="pmid">26811316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r110">
          <label>110</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elbarouni</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ismaeil</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Connelly</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Baer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DeYoung</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Gallo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ramanathan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pesant</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Leiter</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Temporal changes in the management and outcome of Canadian diabetic patients hospitalized for non-ST-elevation acute coronary syndromes.</article-title>
            <source>Am Heart J</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>162</volume>
            <issue>2</issue>
            <fpage>347</fpage>
            <page-range>347-355.e1</page-range>
            <pub-id pub-id-type="pmid">21835297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r111">
          <label>111</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wiviott</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Angiolillo</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Meisel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dalby</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Verheugt</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Corbalan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Purdy</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>McCabe</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Antman</surname>
                <given-names>EM</given-names>
              </name>
              <collab>TRITON-TIMI 38 Investigators</collab>
            </person-group>
            <article-title>Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.</article-title>
            <source>Circulation</source>
            <year>2008</year>
            <month>Oct</month>
            <day>14</day>
            <volume>118</volume>
            <issue>16</issue>
            <fpage>1626</fpage>
            <page-range>1626-36</page-range>
            <pub-id pub-id-type="pmid">18757948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r112">
          <label>112</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farkouh</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Domanski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sleeper</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Siami</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Dangas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Gersh</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Magnuson</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Lansky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boineau</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weinberger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ramanathan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sousa</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Rankin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bhargava</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hueb</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Muratov</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bansilal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bertrand</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fuster</surname>
                <given-names>V</given-names>
              </name>
              <collab>FREEDOM Trial Investigators</collab>
            </person-group>
            <article-title>Strategies for multivessel revascularization in patients with diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>Dec</month>
            <day>20</day>
            <volume>367</volume>
            <issue>25</issue>
            <fpage>2375</fpage>
            <page-range>2375-84</page-range>
            <pub-id pub-id-type="pmid">23121323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r113">
          <label>113</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morel</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Muller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jesel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moulin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hannedouche</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: mechanisms, clinical relevance and pharmacological options.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>28</volume>
            <issue>8</issue>
            <fpage>1994</fpage>
            <page-range>1994-2002</page-range>
            <pub-id pub-id-type="pmid">23476040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r114">
          <label>114</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Navarro</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gosch</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Spertus</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rumsfeld</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Chronic Kidney Disease and Health Status Outcomes Following Acute Myocardial Infarction.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2016</year>
            <month>May</month>
            <day>23</day>
            <volume>5</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">27217497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r115">
          <label>115</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szummer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lundman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;n</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lindb&#x000e4;ck</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stenestrand</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Wallentin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jernberg</surname>
                <given-names>T</given-names>
              </name>
              <collab>SWEDEHEART</collab>
            </person-group>
            <article-title>Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register.</article-title>
            <source>J Intern Med</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>268</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-9</page-range>
            <pub-id pub-id-type="pmid">20210836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r116">
          <label>116</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diercks</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Hiestand</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Pollack</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Kirk</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Gibler</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Blomkalns</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Hochman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Roe</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Frequency and consequences of recording an electrocardiogram &#x0003e;10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE Initiative).</article-title>
            <source>Am J Cardiol</source>
            <year>2006</year>
            <month>Feb</month>
            <day>15</day>
            <volume>97</volume>
            <issue>4</issue>
            <fpage>437</fpage>
            <page-range>437-42</page-range>
            <pub-id pub-id-type="pmid">16461033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r117">
          <label>117</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rokos</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Koenig</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Stratton</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Nighswonger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Strunk</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jewell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mahmud</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dunford</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Hokanson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Baran</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Swor</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Aluko</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Rostykus</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Salvucci</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dev</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>McNally</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Manoukian</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Integration of pre-hospital electrocardiograms and ST-elevation myocardial infarction receiving center (SRC) networks: impact on Door-to-Balloon times across 10 independent regions.</article-title>
            <source>JACC Cardiovasc Interv</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>339</fpage>
            <page-range>339-46</page-range>
            <pub-id pub-id-type="pmid">19463447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r118">
          <label>118</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Doherty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tayler</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chamberlain</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Five hundred patients with myocardial infarction monitored within one hour of symptoms.</article-title>
            <source>Br Med J (Clin Res Ed)</source>
            <year>1983</year>
            <month>Apr</month>
            <day>30</day>
            <volume>286</volume>
            <issue>6375</issue>
            <fpage>1405</fpage>
            <page-range>1405-8</page-range>
            <pub-id pub-id-type="pmid">6404481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r119">
          <label>119</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehta</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Starr</surname>
                <given-names>AZ</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Hochman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Widimsky</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pieper</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <collab>APEX AMI Investigators</collab>
            </person-group>
            <article-title>Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention.</article-title>
            <source>JAMA</source>
            <year>2009</year>
            <month>May</month>
            <day>06</day>
            <volume>301</volume>
            <issue>17</issue>
            <fpage>1779</fpage>
            <page-range>1779-89</page-range>
            <pub-id pub-id-type="pmid">19417195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r120">
          <label>120</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terkelsen</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>S&#x000f8;rensen</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Maeng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>LO</given-names>
              </name>
              <name>
                <surname>Tilsted</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Trautner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vach</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Johnsen</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Thuesen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lassen</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention.</article-title>
            <source>JAMA</source>
            <year>2010</year>
            <month>Aug</month>
            <day>18</day>
            <volume>304</volume>
            <issue>7</issue>
            <fpage>763</fpage>
            <page-range>763-71</page-range>
            <pub-id pub-id-type="pmid">20716739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r121">
          <label>121</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fordyce</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Al-Khalidi</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Jollis</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Roettig</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bagai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Corbett</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Dauerman</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Garvey</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Rokos</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Sherwood</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <collab>STEMI Systems Accelerator Project</collab>
            </person-group>
            <article-title>Association of Rapid Care Process Implementation on Reperfusion Times Across Multiple ST-Segment-Elevation Myocardial Infarction Networks.</article-title>
            <source>Circ Cardiovasc Interv</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>10</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">28082714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r122">
          <label>122</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stowens</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Sonnad</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Using EMS Dispatch to Trigger STEMI Alerts Decreases Door-to-Balloon Times.</article-title>
            <source>West J Emerg Med</source>
            <year>2015</year>
            <month>May</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>472</fpage>
            <page-range>472-80</page-range>
            <pub-id pub-id-type="pmid">25987932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r123">
          <label>123</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Squire</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Tamayo-Sarver</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Rashi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Koenig</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Niemann</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Effect of prehospital cardiac catheterization lab activation on door-to-balloon time, mortality, and false-positive activation.</article-title>
            <source>Prehosp Emerg Care</source>
            <year>2014</year>
            <season>Jan-Mar</season>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">24329031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r124">
          <label>124</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rathore</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nallamothu</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <collab>National Cardiovascular Data Registry</collab>
            </person-group>
            <article-title>Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study.</article-title>
            <source>BMJ</source>
            <year>2009</year>
            <month>May</month>
            <day>19</day>
            <volume>338</volume>
            <fpage>b1807</fpage>
            <pub-id pub-id-type="pmid">19454739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r125">
          <label>125</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nielsen</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Terkelsen</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Thuesen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Krusell</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Thayssen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kelbaek</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Abildgaard</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Villadsen</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Maeng</surname>
                <given-names>M</given-names>
              </name>
              <collab>Danami-2 Investigators</collab>
            </person-group>
            <article-title>System delay and timing of intervention in acute myocardial infarction (from the Danish Acute Myocardial Infarction-2 [DANAMI-2] trial).</article-title>
            <source>Am J Cardiol</source>
            <year>2011</year>
            <month>Sep</month>
            <day>15</day>
            <volume>108</volume>
            <issue>6</issue>
            <fpage>776</fpage>
            <page-range>776-81</page-range>
            <pub-id pub-id-type="pmid">21757183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r126">
          <label>126</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinto</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kirtane</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Nallamothu</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Laham</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Cutlip</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Frederick</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Carrozza</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Antman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy.</article-title>
            <source>Circulation</source>
            <year>2006</year>
            <month>Nov</month>
            <day>07</day>
            <volume>114</volume>
            <issue>19</issue>
            <fpage>2019</fpage>
            <page-range>2019-25</page-range>
            <pub-id pub-id-type="pmid">17075010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r127">
          <label>127</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Widimsky</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wijns</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Fajadet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Belder</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Knot</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aaberge</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Andrikopoulos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Baz</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Betriu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Claeys</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Danchin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Djambazov</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Erne</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hartikainen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kala</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Klinceva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kristensen</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Ludman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ferre</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Merkely</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Milicic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Morais</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Noc</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Opolski</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ostojic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Radovanovic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De Servi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stenestrand</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Studencan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tubaro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vasiljevic</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Weidinger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Witkowski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zeymer</surname>
                <given-names>U</given-names>
              </name>
              <collab>European Association for Percutaneous Cardiovascular Interventions</collab>
            </person-group>
            <article-title>Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries.</article-title>
            <source>Eur Heart J</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>8</issue>
            <fpage>943</fpage>
            <page-range>943-57</page-range>
            <pub-id pub-id-type="pmid">19933242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r128">
          <label>128</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knot</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Widimsky</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wijns</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Stenestrand</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kristensen</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Van' T Hof</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weidinger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Janzon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>N&#x000f6;rgaard</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Soerensen</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>van de Wetering</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Thygesen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bergsten</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Digerfeldt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Potgieter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tomer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fajadet</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>How to set up an effective national primary angioplasty network: lessons learned from five European countries.</article-title>
            <source>EuroIntervention</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>299</fpage>
            <page-range>299, 301-309</page-range>
            <pub-id pub-id-type="pmid">19736153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r129">
          <label>129</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nallamothu</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>LaBresh</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Rathore</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roe</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Schwamm</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Development of systems of care for ST-elevation myocardial infarction patients: gaps, barriers, and implications.</article-title>
            <source>Circulation</source>
            <year>2007</year>
            <month>Jul</month>
            <day>10</day>
            <volume>116</volume>
            <issue>2</issue>
            <fpage>e68</fpage>
            <page-range>e68-72</page-range>
            <pub-id pub-id-type="pmid">17538036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r130">
          <label>130</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bagai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jollis</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Dauerman</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Rokos</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Roe</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Emergency department bypass for ST-Segment-elevation myocardial infarction patients identified with a prehospital electrocardiogram: a report from the American Heart Association Mission: Lifeline program.</article-title>
            <source>Circulation</source>
            <year>2013</year>
            <month>Jul</month>
            <day>23</day>
            <volume>128</volume>
            <issue>4</issue>
            <fpage>352</fpage>
            <page-range>352-9</page-range>
            <pub-id pub-id-type="pmid">23788525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r131">
          <label>131</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalla</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Christ</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Karnik</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Malzer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Norman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Prachar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schreiber</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Glogar</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Kaff</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laggner</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mlczoch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Slany</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>K</given-names>
              </name>
              <collab>Vienna STEMI Registry Group</collab>
            </person-group>
            <article-title>Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI registry).</article-title>
            <source>Circulation</source>
            <year>2006</year>
            <month>May</month>
            <day>23</day>
            <volume>113</volume>
            <issue>20</issue>
            <fpage>2398</fpage>
            <page-range>2398-405</page-range>
            <pub-id pub-id-type="pmid">16702474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r132">
          <label>132</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henry</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Sharkey</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Chavez</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Henry</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Lips</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Madison</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Menssen</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Mooney</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Newell</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Poulose</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Traverse</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction.</article-title>
            <source>Circulation</source>
            <year>2007</year>
            <month>Aug</month>
            <day>14</day>
            <volume>116</volume>
            <issue>7</issue>
            <fpage>721</fpage>
            <page-range>721-8</page-range>
            <pub-id pub-id-type="pmid">17673457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r133">
          <label>133</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Le May</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Dionne</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Glover</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Froeschl</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Sherrard</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Maloney</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marquis</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Trickett</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Poirier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Ha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Joseph</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Labinaz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A citywide protocol for primary PCI in ST-segment elevation myocardial infarction.</article-title>
            <source>N Engl J Med</source>
            <year>2008</year>
            <month>Jan</month>
            <day>17</day>
            <volume>358</volume>
            <issue>3</issue>
            <fpage>231</fpage>
            <page-range>231-40</page-range>
            <pub-id pub-id-type="pmid">18199862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r134">
          <label>134</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hasin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Danchin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Filippatos</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Heras</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Janssens</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Leor</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nahir</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Parkhomenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thygesen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tubaro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wallentin</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Zakke</surname>
                <given-names>I</given-names>
              </name>
              <collab>Working Group on Acute Cardiac Care of the European Society of Cardiology</collab>
            </person-group>
            <article-title>Recommendations for the structure, organization, and operation of intensive cardiac care units.</article-title>
            <source>Eur Heart J</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>16</issue>
            <fpage>1676</fpage>
            <page-range>1676-82</page-range>
            <pub-id pub-id-type="pmid">15781435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r135">
          <label>135</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piepoli</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Hoes</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Agewall</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Albus</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brotons</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Catapano</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Cooney</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Corr&#x000e0;</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Cosyns</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Deaton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>FDR</given-names>
              </name>
              <name>
                <surname>L&#x000f8;chen</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>L&#x000f6;llgen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Marques-Vidal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Perk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Prescott</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Redon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Richter</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Sattar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Smulders</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tiberi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van der Worp</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>van Dis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Verschuren</surname>
                <given-names>WMM</given-names>
              </name>
              <name>
                <surname>Binno</surname>
                <given-names>S</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention &#x00026; Rehabilitation (EACPR).</article-title>
            <source>Eur Heart J</source>
            <year>2016</year>
            <month>Aug</month>
            <day>01</day>
            <volume>37</volume>
            <issue>29</issue>
            <fpage>2315</fpage>
            <page-range>2315-2381</page-range>
            <pub-id pub-id-type="pmid">27222591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r136">
          <label>136</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Oldridge</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Zwisler</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Rees</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-Analysis.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2016</year>
            <month>Jan</month>
            <day>05</day>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">26764059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r137">
          <label>137</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaz-Carneiro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Analysis of the Cochrane Review: Electronic Cigarettes for Smoking Cessation and Reduction. Cochrane Database Syst Rev. 2014,12: CD010216].</article-title>
            <source>Acta Med Port</source>
            <year>2015</year>
            <season>Mar-Apr</season>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>145</fpage>
            <page-range>145-7</page-range>
            <pub-id pub-id-type="pmid">26061503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r138">
          <label>138</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fox</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Brieger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Dabbous</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Avezum</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE).</article-title>
            <source>Eur Heart J</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>15</issue>
            <fpage>1177</fpage>
            <page-range>1177-89</page-range>
            <pub-id pub-id-type="pmid">12127920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r139">
          <label>139</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lenfant</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Shattuck lecture--clinical research to clinical practice--lost in translation?</article-title>
            <source>N Engl J Med</source>
            <year>2003</year>
            <month>Aug</month>
            <day>28</day>
            <volume>349</volume>
            <issue>9</issue>
            <fpage>868</fpage>
            <page-range>868-74</page-range>
            <pub-id pub-id-type="pmid">12944573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-178.r140">
          <label>140</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schiele</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gale</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Bonnefoy</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Capuano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Claeys</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Danchin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iakobishvili</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Lettino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rubini Gimenez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>B&#x000f8;tker</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Swahn</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Timmis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tubaro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vrints</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zahger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zeymer</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Bueno</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Quality indicators for acute myocardial infarction: A position paper of the Acute Cardiovascular Care Association.</article-title>
            <source>Eur Heart J Acute Cardiovasc Care</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-59</page-range>
            <pub-id pub-id-type="pmid">27574334</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
